WO1995005386A1 - Phenethylamine compounds - Google Patents

Phenethylamine compounds Download PDF

Info

Publication number
WO1995005386A1
WO1995005386A1 PCT/US1994/009308 US9409308W WO9505386A1 WO 1995005386 A1 WO1995005386 A1 WO 1995005386A1 US 9409308 W US9409308 W US 9409308W WO 9505386 A1 WO9505386 A1 WO 9505386A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
hydrogen
amine
ncn
Prior art date
Application number
PCT/US1994/009308
Other languages
French (fr)
Inventor
Siegfried Benjamin Christensen, Iv
Cornelia Jutta Forster
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to US08/596,197 priority Critical patent/US5710180A/en
Priority to JP7507173A priority patent/JPH09502170A/en
Priority to EP94925286A priority patent/EP0714397A1/en
Publication of WO1995005386A1 publication Critical patent/WO1995005386A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C261/00—Derivatives of cyanic acid
    • C07C261/04—Cyanamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/10—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/58—Y being a hetero atom
    • C07C275/62—Y being a nitrogen atom, e.g. biuret
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4062—Esters of acids containing the structure -C(=X)-P(=X)(XR)2 or NC-P(=X)(XR)2, (X = O, S, Se)
    • C07F9/4065—Esters of acids containing the structure -C(=X)-P(=X)(XR)2, (X = O, S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/44—Amides thereof
    • C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/443—Amides of acids containing the structure -C(=Y)-P(=X)(XR)-N or NC-(P(=X)(XR)-N )
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

  • Bronchial asthma is a complex, multifactorial disease characterized by reversible narrowing of the airway and hyper-reactivity of the respiratory tract to external stimuli. It is now understood that the symptoms of chronic asthma are the manifestations of three distinct processes: 1) an early response to antigen, 2) a delayed or late response to antigen, and 3) chronic inflammation and airway hyper-reactivity. Cockcroft, Ann. Allergy 55:857-862, 1985; Larsen, Hosp. Practice 22:113-127, 1987.
  • the agents currently available ⁇ -adrenoceptor agonists, steroids, methylxanthines, disodium cromoglycate
  • Cyclic AMP modulates the activity of most, if not all, of the cells that contribute to the pathophysiology of extrinsic (allergic) asthma. As such, an elevation of cAMP would produce beneficial effects including: 1) airway smooth muscle relaxation, 2) inhibition of mast cell mediator release, 3) suppression of neutrophil degranulation, 4) inhibition of basophil degranulation, and 5) inhibition of monocyte and macrophage activation.
  • compounds that activate adenylate cyclase or inhibit PDE should be effective in suppressing the inappropriate activation of airway smooth muscle and a wide variety of inflammatory cells.
  • the principal cellular mechanism for the inactivation of c AMP is hydrolysis of the 3'-phosphodiester bond by one or more of a family of isozymes referred to as cyclic nucleotide phosphodiesterases (PDEs).
  • PDE IN cyclic nucleotide phosphodiesterase
  • PDE IV inhibitors are markedly potentiated when adenylate cyclase activity of target cells is elevated by appropriate hormones or autocoids, as would be the case in vivo.
  • PDE IV inhibitors would be effective in the asthmatic lung, where levels of prostaglandin E2 and prostacyclin (activators of adenylate cyclase) are elevated.
  • Such compounds would offer a unique approach toward the pharmacotherapy of bronchial asthma and possess significant therapeutic advantages over agents currently on the market.
  • TNF Tumor Necrosis Factor
  • rheumatoid arthritis rheumatoid spondylitis
  • osteoarthritis gouty arthritis and other arthritic conditions
  • sepsis septic shock, endotoxic shock, gram negative sepsis
  • toxic shock syndrome adult respiratory distress syndrome
  • cerebral malaria chronic pulmonary inflammatory disease
  • silicosis pulmonary sacroidosis
  • bone resoiption diseases reperfusion injury, graft vs.
  • allograft rejections fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis.
  • AIDS cachexia secondary to infection or malignancy
  • AIDS cachexia secondary to acquired immune deficiency syndrome
  • AIDS AIDS
  • ARC AIDS related complex
  • keloid formation scar tissue formation
  • Crohn's disease Crohn's disease
  • ulcerative colitis or pyresis.
  • TNF has been implicated in various roles with the human acquired immune deficiency syndrome (AIDS). AIDS results from the infection of T lymphocytes with Human Immunodeficiency Virus (HIV).
  • HIV Human Immunodeficiency Virus
  • monokines, specifically TNF are implicated in the infection of T lymphocytes with HTV by playing a role in maintaining T lymphocyte activation.
  • monokines, specifically T ⁇ F are implicated in activated T cell-mediated HIN protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation.
  • interference with monokine activity such as by inhibition of monokine production, notably T ⁇ F, in an HTV-infected individual aids in Umiting the maintenance of T cell activation, thereby reducing the progression of HIN infectivity to previously uninfected cells which results in a slowing or elimination of the progression of immune dysfunction caused by HIN infection.
  • Monocytes, macrophages, and related cells such as kupffer and glial cells, have also been implicated in maintenance of the HIN infection. These cells, like T cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells. [See Rosenberg et al., The Immunopatho-genesis of HTV Infection, Advances in Immunology, Vol. 57, (1989)].
  • Monokines such as TNF have been shown to activate HTV replication in monocytes and/or macrophages [See Poli, et al., Proc. Natl. Acad. Sci., 87:782-784 (1990)], therefore, inhibition of monokine production or activity aids in limiting HTV progression as stated above for T cells.
  • monokine activity such as by inhibition of TNF production
  • an HlV-infected individual aids in enhancing the quality of life of HTV-infected patients by reducing the severity of monokine-mediated disease associated problems such as cachexia and muscle degeneration.
  • TNF is also associated with yeast and fungal infections. Specifically Candida Albicans has been shown to induce TNF production in vitro in human monocytes and natural killer cells. [See Riipi et al., Infection and Immunity, Vol. 58, No.9, p.2750-54 (1990); and Jafari et al., Journal of Infectious Diseases, Vol. 164, p. 389-95 (1991). See also Wasan et al., Antimicrobial Agents and Chemotherapy, Vol. 35, No. 10, p. 2046-48 (1991) and Luke et al., Journal of Infectious Diseases, Vol. 162, p.211-214 (1990)].
  • the discovery of a class of compounds which inhibit the production of TNF will provide a therapeutic approach for the diseases in which excessive, or unregulated TNF production is implicated. That is provided herewith.
  • this invention covers a compound of formula I
  • Rl is lower alkyl substituted by 1 or more halogens, aryl, halo substituted aryl, aryloxyCl-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, C7-11 polycycloalkyl, tetrahydrofuryl, furyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, -CR4R5-C3-6 cycloalkyl, C3-6 cycloalkyl, or a C4-6 cycloalkenyl containing one or two unsaturated bonds, wherein the cycloalkyl and heterocyclyl moieties unsubstituted or substituted by 1 to 3 methyl groups or one ethyl group;
  • R2 is -CH3 or -CH2CH3 unsubstituted or substituted by 1 or more halogens
  • R3 is lower alkyl unsubstituted or substituted by one or more halogens, -CR4R5OR4, -CR4R5NR4R9, -CR4(OR4)CR4R5OR4, 2,2-dimethyl- 1 ,3-dioxolan-4-yl, -NR9C(O)NR4R9, -NR4R9, -S(CR4 5) n CH3 where n is 0-5, or -P(O)(ORi2)2;
  • R4 and R5 are independently hydrogen, methyl or ethyl
  • R8 is H, F, CN, Cl-2 alkyl optionally substituted by 1 or more fluoro groups,
  • R9 is H, -ORi 1, unsubstituted or substituted -(CH2) m Ar where m is 0-2, or unsubstituted or substituted Ci-6 alkyl, wherein optional substituents comprise from one to three groups independently selected from the group consisting of -CH3 or -CH2CH3 unsubstituted or substituted by 1 or more halogens, -NO2, -Si(R4)3, -NRJORU, - C(O)R4, -C(O)OR4, -OR4, -CN, -C(O)NRioRll, -OC(O)NRioRll, -OC(O)Ri2, -NRi ⁇ C(O)NRi ⁇ Rll, -NR ⁇ oC(O)Rn, -NRioC(O)ORi2, -NRioC(O)Ri3, -C(NR ⁇ o)NRioRll, -C(NCN)NR ⁇ oRll, -
  • RiO is -ORil or -Rn
  • Rl 1 is hydrogen, or -C1.4 alkyl unsubstituted or substituted by one to three fluoro groups; or when Rio and Rl 1 are comprise part of the group -NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring which may contain at least one additional heteroatom which is O, N, or S;
  • Rj2 s -C ⁇ _4 alkyl unsubstituted or substituted by one to three fluoro groups
  • Rl3 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, wherein each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two C ⁇ _2 alkyl groups
  • R14 is OH or OR12;
  • Rl5 is unsubstituted or substituted -(CH2) m Ar where m is 0-2, or unsubstituted or substituted Ci-6 alkyl, wherein optional substituents comprise from one to three groups independently selected from the group consisting of -CH3 or -CH2CH3 unsubstituted or substituted by 1 or more halogens, -NO2, -Si(R4)3, -NRIQRH, -C(O)R4, -C(O)OR4, -OR4, -CN, -C(O)NR ⁇ oRl 1, -OC(O)NRioRl 1, -OC(O)Ri2, -NR ⁇ oC(O)NR ⁇ oRll, -NR ⁇ oC(O)Rn, -NRioC(O)ORi2, -NRi()C(O)Ri3, -C(NR ⁇ o)NRioRll, -C(NCN)NRl ⁇ Rll, -C(NCN)
  • AT is 2-, 3- or 4-pyridyl, pyrimidyl, pyridazyl, 2-imidazolyl, mo holino, or phenyl;
  • Xl is YR2, halogen, nitro, -NR4R5, or formyl amine;
  • X2 is O or NR4
  • X3 is hydrogen or X ⁇ ;
  • Y is O, S, SO or SO2;
  • Z is O or NCN; provided that a) Z is NCN only when R3 is -NR4R5 or -S(CR4R5) n CH3; or b) when Xi is -NR4R5 or formyl amine, then Rl is not CH3 or C2H5 when X2 is O and X3 is H or halogen; or c) when R3 is CR4R5NR4R9, and X2 is O, and Rl is phenyl, then one of R6.
  • R7, or R8 is other than H; or d) when Z is NCN, and X 1 is YR2, and Y is O, and R2 is CH3 and R3 is NH2, and R9 is H, OH, OCH3 or CH3, and R8 is H, and R6 and R7 are both hydrogen, or are hydrogen and methyl, hydrogen and CF3 or hydrogen and ethyl, and X2 is O, then Rl is not CF3, CF2H, or CF2CF2H; or e) when Z is NCN, and X is YR2» and Y is O, and R2 is CH3 and R3 is NH2, and R9 is H, OH, OCH3 or CH3, and R8 is H, and R6 and R7 are both hydrogen, or are hydrogen and methyl, hydrogen and CF3 or hydrogen and ethyl, and X2 is NR4 and R4 is CH3, then Ri is not CH3; or f) when Q is A, and X2 is
  • novel compounds of the Formula (I) also have Tumor Necrosis Factor (TNF) inhibitory activity.
  • TNF Tumor Necrosis Factor
  • This invention also relates to a composition, including a pharmaceutical composition, comprising a compound of the Formula I and a carrier or diluent
  • the invention also relates to a method of mediation or inhibition of the enzymatic activity (or catalytic activity) of phosphodiesterase IV, including mammals which comprises administering to a mammal in need thereof an effective amount of a compound of Formula I.
  • the invention further provides a method for treating allergic and inflammatory diseases which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of the Formula I.
  • the invention also provides a method for treating asthma which comprises administering to a mammal, including humans, in need thereof an effective amount of a compound of the Formula I.
  • This invention also relates to a method of inhibiting TNF production in a mammal, including humans, which method comprises administering to a mammal in need of such treatment an effective TNF inhibiting amount of a compound of the Formula (I).
  • This method may be used for the prophylactic treatment or prevention of certain TNF mediated disease states amenable thereto.
  • This invention also relates to a method of treating a human afflicted with a human immunodeficiency virus (HIV), which comprises administering to such human an effective TNF inhibiting amount of a compound of the Formula (I).
  • HAV human immunodeficiency virus
  • the compounds of the Formula (I) are also useful in the treatment of additional viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo.
  • this invention covers a process for making a compound of formula I, which process comprises one or more of the following steps: a) forming a salt; b) treating an amine with a lower alkyl acylating agent to form the corresponding amide; c) treating an amine with biuret to form the corresponding imidodicarbamide; d) hydrolyzing the product of an amine treated with trimethylsilyl isocyanate to form the corresponding urea; e) treating an amine with cyanodithioiminiocarbonate to form the corresponding N ⁇ -cyano-S -methyl-N * -isothiouriedo; f) treating an N ⁇ -cyano-S-methyl-N*- isothiouriedo with an amine to form the corresponding N'-cyanocarboximidamide; g) treating a amine with a mixture comprising (4S )-2,2-dimethyl- 1 ,3- dioxolane-4-carboxy
  • “Lower alkyl” means a group having 1 to 6 carbon atoms. This included normal, secondary and tertiary form where such forms can exist e.g., isopropyl, t-butyl and the like. Normal, or linear, radicals are preferred, especially methyl, ethyl, propyl, butyl, pentyl and hexyl.
  • Halo means fluoro, chloro, bromo and iodo.
  • cycloalkyl or "cycloalkyl alkyl” as used herein is meant to include those rings of 3-7 carbon atoms, such as cyclopropyl, cyclopropylmethyl, cyclopentyl or cyclohexyl.
  • Aryl unless specified otherwise, means an aromatic ring or ring system of 6-10 carbon atoms such as phenyl. Preferably the aryl is monocyclic, i.e., phenyl.
  • the alkyl chain is meant to include both straight or branched chain radicals of 1 to 4 carbon atoms.
  • Inhibiting the production of TNF means, a) a decrease of excessive ia vivo TNF levels in a human to normal levels or below normal levels by inhibition of the in vivo release of TNF by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the translational or transcription level, of excessive in vivo TNF levels in a human to normal levels or below normal levels; or c) a down regulation, by inhibition of the direct synthesis of TNF as a postranslational event 'TNF mediated disease states” means all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL-1, or IL-6.
  • Cytokine means any secreted polypeptide that affects the functions of other cells, and is a molecule which modulates interactions between cells in the immune or inflammatory response.
  • a cytokine includes, but is not limited to monokines and lymphokines regardless of which cells produce them.
  • a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte but many other cells produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epideral keratinocytes, and ⁇ -lymphocytes.
  • monokines such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epideral keratinocytes, and ⁇ -lymphocytes.
  • Lymphokines are generally referred to as being produced by lymphocyte cells.
  • cytokines examples include, but are not limited to Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF- ⁇ ) and Tumor Necrosis Factor beta (TNF ⁇ ).
  • IL-1 Interleukin-1
  • IL-6 Interleukin-6
  • TNF- ⁇ Tumor Necrosis Factor-alpha
  • TNF ⁇ Tumor Necrosis Factor beta
  • Some compounds of formula I may exist in two distinct enantiomeric forms. Some compounds of Formula I may exist in at least two distinct diasteriomeric forms possessing distinct physical and biological properties. Furthermore some compounds of Formula I may exist in a tautomeric form, such as the enol or enamine. All these forms are within the scope of this invention.
  • Rl groups are cyclopropylmethyl, cyclopentymethyl, cyclohexylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, tet ⁇ ahydrofur-2-yl, cyclopentenyl, benzyl, or lower alkyl optionally substituted by 1 or more fluoro groups.
  • the halogens are preferably fluorine and chlorine, more preferably a Ci-4 alkyl substituted by 1 or more fluoro groups, more preferably 1 or more times by fluorine.
  • halo substituted chain length is one or two carbons, and most preferred are the moieties -CF3, -CH2F, -CHF2, -CF2CHF2, -CH2CF3, and - CH2CHF2.
  • Preferred Ri substitutents are cyclopentyl, cyclopropylmethyl, -CF3, and - CHF2.
  • R 1 is a C7.1 1 polycycloalkyl
  • examples are bicyclo[2.2.1 ]-heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, tricyclo 5.2.1.0 2 » 6 ]decyl, additional examples of which are described in Saccamano et al., WO 87/06576, published 5 November 1987 which is incorporated herein by reference in its entirety.
  • Oxygen is the preferred X2 radical.
  • the preferred radical is YR2 where Y is oxygen.
  • the preferred R2 group is a methyl or ethyl unsubstituted or substituted by 1 or more halogens.
  • the preferred halogens are fluoro and chloro, most preferably fluoro.
  • the more preferred R2 groups are methyl, -CF3, -CHF2, or -CH2CHF2 moiety. Most preferred are difluoromethyl and methyl.
  • Hydrogen is the referred X3 radical.
  • the preferred radicals are those which form an amide, sulfonamide, imidodicarbamide, urea, N ⁇ -cyano-S-methyl-NMso ⁇ iouriedo, 2,3- dihydroxypropanamide, 2,2-ctimethyl-l,3-dioxolane-4-carboxamide, 2-acetoxyacetamide, or a 2-aminoacetamide.
  • R6 moieties are H, C(O)NH2, C ⁇ CR4, CN, C(O)H, CH2OH, CH2F, CF2H, and CF3. More preferred are C ⁇ CH and CN.
  • R7 is preferably H or CN.
  • R ⁇ is preferably H, -C(O)NH2 or CN.
  • Preferred R9 moieties include hydrogen, optionally substituted -(CH2)0-2(2-, 3- or4-pyridyl), (CH2)l-2(2-imidazolyl), (CH2)2(4-morpholinyl), (CH2)2(4-piperazinyl), (CH2)l-2(2-thienyl), (CH2)l-2(4-thiazolyl), and (CH2)0-2phenyl.
  • Preferred rings when Rio and Ri 1 in the moiety -NRioRl 1 together with the nitrogen to which they are attached form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S include, but are not limited to 1- imidazolyl, 2-(R8)-l-imidazolyl, 1-pyrazolyl, 3-(R8)-l -pyrazolyl, 1-triazolyl, 2-triazolyl, 5-(R8)-l-triazolyl, 5-(R8)-2-triazolyl, 5-(R8)-l-tetrazolyl, 5-(R8)-2-tetrazolyl, 1- tetrazolyl, 2-tetrazloyl, morpholinyl, piperazinyl, 4-(R8)-l-piperazinyl, or pyrrolyl ring.
  • Preferred R15 moieties include, optionally substituted Ci-3alkyl, -(CH2)0-2(2-,
  • Preferred rings for R13 include (2-, 4- or 5-imidazolyl), (3-, 4- or 5-pyrazolyl), (4- or 5-triazolyl[l,2,3]), (3- or 5-triazolyl[ 1,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5-isoxazolyl), (3- or 5-oxadiazolyl[ 1,2,4]), (2-oxadiazolyl[ 1,3,4]),
  • R2 is methyl or fluoro-substituted alkyl
  • R6 is CN or C ⁇ CR4
  • X is YR2-
  • Ri is -CH2-cyclopropyl, cyclopentyl, or CF2H
  • Rg is CN or C ⁇ CH
  • X is YR2
  • Y is oxygen
  • X2 is oxygen
  • X3 is hydrogen
  • R2 is CF2H or methyl.
  • Phosphodiesterase TV inhibitors are useful in the treatment of a variety of allergic and inflammatory diseases including: asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, inflammatory bowel disease states including Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.
  • PDE TV inhibitors are useful in treating diabetes insipidus, (Kidnev Int. 37:362, 1990; Kidnev Int. 35:494, 1989) and central nervous system disorders such as depression and multi-infarct dementia.
  • Compounds of Formula I are useful in treating, prophylactically or therapeutically, disease states in humans which are exacerbated or caused by excessive or unregulated
  • the present invention also provides a method for inhibiting the production of tumor necrosis factor (TNF) in an animal in need thereof, including humans, which method comprises administering to said animal an effective amount of a compound of formula I alone or mixed with a carrier.
  • TNF tumor necrosis factor
  • Compounds of the Formula I may be administered systemically, topically, parenterally or by inhalation in conventional dosage forms prepared by combining such agent with standard carriers according to conventional procedures in an amount sufficient to produce the desired therapeutic activity for treatment of a TNF-mediated disease state or for use as a PDE TV inhibitor.
  • the daily dosage regimen is suitably about .001 mg/kg to lOOmg/kg, preferably 0.01 mg Kg to 40 mg/Kg, of a compound of the Formula I or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit activity.
  • compositions of the present invention will comprising an effective, non-toxic amount of a compound of the formula I and a pharmaceutically acceptable carrier or diluent
  • a pharmaceutically acceptable carrier or diluent The carriers) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious in the intended use.
  • the composition is in unit dosage form, for example a tablet capsule or metered aerosol dose, so that the patient may self-administer a single dose.
  • systemic administration oral, intravenous, intraperitoneal, topical, inhalation and intramuscular administration.
  • topical administration is meant non- systemic administration and includes the application of a compound externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the compound does not significantly enter the blood stream.
  • parenteral' as used herein includes intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred.
  • each dosage unit may contains from 1 mg to 100 mg, and preferably from 10 mg to 30 mg of a compound of the formula I or a pharmaceutically acceptable salt thereof calculated as the free base.
  • Appropriate dosage forms for inhalation include an aerosol formulation or a metered dose inhaler.
  • the daily dosage regimen for a compound of the Formula (I) for intranasal administration and oral inhalation is suitably about 10 to about 1200 mg.
  • a suitable dose of a TNF production inhibiting compound of the formula I is from about 0.01 mg to about 100 mg of base for topical administration, the most preferred dosage being about 0.01 mg to about 30 mg, for example, 0.003 mg to 10 mg administered two or three times daily.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. No unacceptable toxicological effects are expected when these compounds are administered in accordance with the present invention.
  • an amine is first prepared, that is a compound where R is NH2, and then this intermediate is converted to the desired target compound by one or more steps, all of which are described below.
  • These amines can be prepared by the methods set out in PCT/US91/04795; those processes and the amines disclosed there are incorporated herein by reference to the extent that information is necessary or useful for understanding how to make the amine precursors used in this work.
  • a reducing agent such as lithium aluminum anhydride or hydrogen
  • the aldehyde of formula a can be treated with a lithium halide and a silyl halide in an appropriate solvent followed by a reducing agent e.g., siloxane, providing a halide of formula (c)
  • X4 is the halogen derived from the lithium halide.
  • Cyanide is then used to displace the halide.
  • This nitrile is then reduced, for example by hydrogen and suitable heavy metal catalyst such as nickel with ammonia or palladium on carbon with an acid such as perchloric acid to obtain the primary amine.
  • R6 is nitrile
  • such compounds can be prepared by dehydrating a compound of formula (d)
  • the reaction mixture was cooled to 0°C and quenched by the successive dropwise addition of water (11 mL), 15% sodium hydroxide (11 mL) and water (33 mL).
  • the mixture was filtered through a pad of Celite and the filtrate was washed successively with water, 10% hydrochloric acid and water.
  • the aqueous washes were combined, made basic with saturated aqueous potassium carbonate and extracted three times with ether and twice with methylene chloride.
  • the organic layers were combined and dried (potassium carbonate). Removal of the solvent in vacuo provided the amine.
  • a portion of the crude amine was purified by flash chromatography, eluting with 1:10:90 water/methanol/chloroform. Analysis Calc.
  • Example 4 Dimethyl N-r2-f3-cvclopentvloxv-4-methoxvphenvnethvnphosphonoformamide A mixture of trimethyl phosphonoformate (0.27 mL, 2.0 mmol) and 2-(3- cyclopentyloxy-4-methoxyphenyl)ethylamine (0.47 g, 2.0 mmol) was allowed to stand under an argon atmosphere for 3h. During this time, the mixture was sonicated twice for 3 min. The mixture was dissolved in methylene chloride and washed successively with 10% hydrochloric acid and water and dried (potassium carbonate).
  • the mixture was concentrated under reduced pressure, dissolved in tetrahydrofuran (2 mL) and added to a -78°C solution containing 2-(3-cyclopentyloxy-4-methoxyphenyl)ethylamine (0.48 g, 2.0 mmol) and diisopropylethylamine (0.39 mL, 2.2 mmol) in tetrahydrofuran (3 mL) under an argon atmosphere.
  • the reaction mixture was stirred for 1.5h at -78°C and quenched by the addition of ammonium chloride.
  • the solvent was removed under reduced pressure, and the residue was partitioned between dilute aqueous hydrochloric acid and methylene chloride.
  • N-r2-r3-Cvclopentvloxv-4-methoxvphenvnethvnacetamide 10a N-(t-ButoxvcarbonvlV2-r3-cvclopentvloxv-4-methoxvphenvnethvlamine
  • a solution of 2-(3-cyclopentyloxy-4-methoxyphenyl)ethylamine (2.5 g, 10.6 mmol) in methylene chloride (25 mL) was treated with t-butyloxycarbonylanhydride (2.5 mL, 11 mmol) and stirred under an argon atmosphere for 2h.
  • N-r2-Cvano-2-f3-cvclopentvloxv-4-methoxvphenvnethvn-2-hvdroxvacetamide 13a ⁇ -Bromo-3-cyclopentyloxy-4-methoxytoluene
  • lithium bromide 3.94 g, 45.4 mmol
  • acetonitrile 25 mL
  • Trimethylsilyl chloride 4.32 mL, 34.0 mmol
  • N-r2-Cvano-2-f3-cvclopentvloxv-4-methoxvphenvnethvn-2-acetoxvacetamide A solution of 3-amino-2-(3-cyclopentyloxy-4-methoxyphenyl)propionitrile (0.095 g, 0.36 mmol) in methylene chloride (2 mL) was cooled to 0°C and was treated with methylamine (0.057 mL, 0.43 mmol) and acetoacetyl chloride (0.045 mL, 0.4 mmol).
  • N-r2-Cyano-2-(3-cyclopentyloxy-4-methoxyphenvDethyll-2-hvdroxyacetamide A solution of N-[2-cyano-2-(3-cyclopentyloxy-4-methoxyphenyl)ethyl]-2-acetoxyacetamide (0.102 g, 0.28 mmol) in methanol (5 mL) was treated with powdered potassium carbonate (0.096 g, 0.69 mmol) and stirred for 15 min. The mixture was diluted with water, was extracted three times with methylene chloride and the organic extract was dried (potassium carbonate) and evaporated.
  • N-r2-(3-Cvclopentvloxv-4-methoxvphenvnethvl1-2-t-butvloxvcarbonvlamino- acetamide A solution of 3-cyclopentyloxy-4-methoxyphenethylamine (0.32 g, 1.37 mmol) in methylene chloride (5 mL) at room temperature under an argon atmosphere was treated with triethylamine (0.19 mL, 1.37 mmol), N,N-dimethylaminopyridine (0.17 g, 1.37 mmol) and N-t-butyloxycarbonylglycine-N-hydroxysuccinimide ester (0.37 g, 1.37 mmol).
  • N-[2-(3-cyclopentyloxy-4-memoxyphenyl)ethyl]-2-t-butyloxycarrx)nylam__noacetamide (0.53 g, 1.35 mmol) in methylene chloride (16 mL) cooled to 0° C was treated with the dropwise addition of trifluoroacetic acid (1.7 mL), was allowed to come to room temperature and was stirred for 2.5h. The liquids were evaporated, the residue was partitioned between methylene chloride and saturated aqueous sodium bicarbonate and was extracted three times. The organic extract was dried (potassium carbonate) and evaporated.
  • a compound of formula I, (1 ⁇ g to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
  • Step 1 Blend ingredients No. 1, No.2, No. 3 and No. 4 in a suitable mixer/blender.
  • Step 2 Add sufficient water portion- wise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its conversion to wet granules.
  • Step 3 The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
  • Step 4 The wet granules are then dried in an oven at 140°F (60°C) until dry.
  • Step 5 The dry granules are lubricated with ingredient No. 5.
  • Step 6 The lubricated granules are compressed on a suitable tablet press.
  • a pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount f a compound of formula I in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then sterilized by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Abstract

Substituted phenethylamines of formula (I) useful for treating phosphodiesterase IV related disease states are disclosed herein.

Description

PHENETHYLAMINE COMPOUNDS
Field of the Invention
This invention relates to certain phenethylamines which are useful for treating diseases where antagonizing the enzyme phosphodiesterase IN will have a salutory effect Background of the Invention
Bronchial asthma is a complex, multifactorial disease characterized by reversible narrowing of the airway and hyper-reactivity of the respiratory tract to external stimuli. It is now understood that the symptoms of chronic asthma are the manifestations of three distinct processes: 1) an early response to antigen, 2) a delayed or late response to antigen, and 3) chronic inflammation and airway hyper-reactivity. Cockcroft, Ann. Allergy 55:857-862, 1985; Larsen, Hosp. Practice 22:113-127, 1987. The agents currently available (β-adrenoceptor agonists, steroids, methylxanthines, disodium cromoglycate) are inadequate to control the disease; none of them modify all three phases of asthma and nearly all are saddled with limiting side effects. Most importantly, none of the agents, with the possible exception of steroids, alter the course of progression of chronic asthma.
Identification of novel therapeutic agents for asthma is made difficult by the fact that multiple mediators are responsible for the development of disease. Thus, it seems unlikely that eliminating the effects of a single mediator will have a substantial effect on all three components of chronic asthma. An alternative to the "mediator approach" is to regulate the activity of the cells responsible for the pathophysiology of the disease.
Cyclic AMP modulates the activity of most, if not all, of the cells that contribute to the pathophysiology of extrinsic (allergic) asthma. As such, an elevation of cAMP would produce beneficial effects including: 1) airway smooth muscle relaxation, 2) inhibition of mast cell mediator release, 3) suppression of neutrophil degranulation, 4) inhibition of basophil degranulation, and 5) inhibition of monocyte and macrophage activation. Hence, compounds that activate adenylate cyclase or inhibit PDE should be effective in suppressing the inappropriate activation of airway smooth muscle and a wide variety of inflammatory cells. The principal cellular mechanism for the inactivation of c AMP is hydrolysis of the 3'-phosphodiester bond by one or more of a family of isozymes referred to as cyclic nucleotide phosphodiesterases (PDEs).
It has now been shown that a distinct cyclic nucleotide phosphodiesterase (PDE) isozyme, PDE IN, is responsible for cyclic AMP breakdown in airway smooth muscle and inflammatory cells. Toiphy, "Phosphodiesterase Isozymes: Potential Targets for Novel Anti-asthmatic Agents" in New Drugs for Asthma, Barnes, ed. IBC Technical Services Ltd. (1989). Research indicates that inhibition of this enzyme not only produces airway smooth muscle relaxation, but also suppresses degranulation of mast cells, basophils and neutrophils along with inhibiting the activation of monocytes and neutrophils. Moreover, the beneficial effects of PDE IV inhibitors are markedly potentiated when adenylate cyclase activity of target cells is elevated by appropriate hormones or autocoids, as would be the case in vivo. Thus PDE IV inhibitors would be effective in the asthmatic lung, where levels of prostaglandin E2 and prostacyclin (activators of adenylate cyclase) are elevated. Such compounds would offer a unique approach toward the pharmacotherapy of bronchial asthma and possess significant therapeutic advantages over agents currently on the market.
The compounds of this invention also inhibit production of Tumor Necrosis Factor (TNF), a serum glycoprotein. Excessive or unregulated TNF production is implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sacroidosis, bone resoiption diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis.
TNF has been implicated in various roles with the human acquired immune deficiency syndrome (AIDS). AIDS results from the infection of T lymphocytes with Human Immunodeficiency Virus (HIV). It has now been discovered that monokines, specifically TNF, are implicated in the infection of T lymphocytes with HTV by playing a role in maintaining T lymphocyte activation. Furthermore, once an activated T lymphocyte is infected with HTV, the T lymphocyte must continue to be maintained in an activated state to permit HIN gene expression and/or HTV replication. It has also been discovered that monokines, specifically TΝF, are implicated in activated T cell-mediated HIN protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation. Therefore, interference with monokine activity such as by inhibition of monokine production, notably TΝF, in an HTV-infected individual aids in Umiting the maintenance of T cell activation, thereby reducing the progression of HIN infectivity to previously uninfected cells which results in a slowing or elimination of the progression of immune dysfunction caused by HIN infection. Monocytes, macrophages, and related cells, such as kupffer and glial cells, have also been implicated in maintenance of the HIN infection. These cells, like T cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells. [See Rosenberg et al., The Immunopatho-genesis of HTV Infection, Advances in Immunology, Vol. 57, (1989)]. Monokines, such as TNF, have been shown to activate HTV replication in monocytes and/or macrophages [See Poli, et al., Proc. Natl. Acad. Sci., 87:782-784 (1990)], therefore, inhibition of monokine production or activity aids in limiting HTV progression as stated above for T cells.
It has now been discovered that monokines are implicated in certain disease- associated problems such as cachexia and muscle degeneration. Therefore, interference with monokine activity, such as by inhibition of TNF production, in an HlV-infected individual aids in enhancing the quality of life of HTV-infected patients by reducing the severity of monokine-mediated disease associated problems such as cachexia and muscle degeneration.
TNF is also associated with yeast and fungal infections. Specifically Candida Albicans has been shown to induce TNF production in vitro in human monocytes and natural killer cells. [See Riipi et al., Infection and Immunity, Vol. 58, No.9, p.2750-54 (1990); and Jafari et al., Journal of Infectious Diseases, Vol. 164, p. 389-95 (1991). See also Wasan et al., Antimicrobial Agents and Chemotherapy, Vol. 35, No. 10, p. 2046-48 (1991) and Luke et al., Journal of Infectious Diseases, Vol. 162, p.211-214 (1990)]. The discovery of a class of compounds which inhibit the production of TNF will provide a therapeutic approach for the diseases in which excessive, or unregulated TNF production is implicated. That is provided herewith.
Summary of the Invention In a first aspect, this invention covers a compound of formula I
Figure imgf000005_0001
or a salt thereof, where Q is a radical of formula A, B, C or D
Figure imgf000005_0002
Rl is lower alkyl substituted by 1 or more halogens, aryl, halo substituted aryl, aryloxyCl-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, C7-11 polycycloalkyl, tetrahydrofuryl, furyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, -CR4R5-C3-6 cycloalkyl, C3-6 cycloalkyl, or a C4-6 cycloalkenyl containing one or two unsaturated bonds, wherein the cycloalkyl and heterocyclyl moieties unsubstituted or substituted by 1 to 3 methyl groups or one ethyl group;
R2 is -CH3 or -CH2CH3 unsubstituted or substituted by 1 or more halogens;
R3 is lower alkyl unsubstituted or substituted by one or more halogens, -CR4R5OR4, -CR4R5NR4R9, -CR4(OR4)CR4R5OR4, 2,2-dimethyl- 1 ,3-dioxolan-4-yl, -NR9C(O)NR4R9, -NR4R9, -S(CR4 5)nCH3 where n is 0-5, or -P(O)(ORi2)2;
R4 and R5 are independently hydrogen, methyl or ethyl;
Rg is hydrogen, halogen, -C1-4 alkyl, halo-substituted C1-4 alkyl, -CH2NHC(O)C(O)NH2, -CH=CR4R5, cyclopropyl unsubstituted or substituted by R4, -CN, -OR4, -CH2OR4, -NR4R5, -CH2NR4R5, -C(O)R4, -C(O)OR4, -C(O)NR4R5, or -C≡CR4; provided that when R6 is OH, then R7 is hydrogen or -CH3 unsubstituted or substituted by 1 to 3 fluoro groups;
R7 is hydrogen, F, -CN, or -CH3 unsubstituted or substituted by 1 to 3 fluoro groups, or R6 and R7 together can form a keto (=O) moiety; R8 is H, F, CN, Cl-2 alkyl optionally substituted by 1 or more fluoro groups,
C(O)NR4R5, or C(O)OR4;
R9 is H, -ORi 1, unsubstituted or substituted -(CH2)mAr where m is 0-2, or unsubstituted or substituted Ci-6 alkyl, wherein optional substituents comprise from one to three groups independently selected from the group consisting of -CH3 or -CH2CH3 unsubstituted or substituted by 1 or more halogens, -NO2, -Si(R4)3, -NRJORU, - C(O)R4, -C(O)OR4, -OR4, -CN, -C(O)NRioRll, -OC(O)NRioRll, -OC(O)Ri2, -NRiθC(O)NRiθRll, -NRιoC(O)Rn, -NRioC(O)ORi2, -NRioC(O)Ri3, -C(NRιo)NRioRll, -C(NCN)NRιoRll, -C(NCN)SR9, -NRlθC(NCN)SR9 , -NRiθC(NCN)NRιoRll, -NRιoS(O)2Rl2, -S(O)m'Rl2 where m' is 0-2, -NRiθC(O)C(O)NRιoRl 1, -NRioC(O)C(O)Rιo, thiazolyl, imidazolyl, oxazolyl, pyrazolyl, triazolyl, and tetrazolyl;
RiO is -ORil or -Rn;
Rl 1 is hydrogen, or -C1.4 alkyl unsubstituted or substituted by one to three fluoro groups; or when Rio and Rl 1 are comprise part of the group -NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring which may contain at least one additional heteroatom which is O, N, or S;
Rj2 s -Cι_4 alkyl unsubstituted or substituted by one to three fluoro groups; Rl3 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, wherein each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two Cι_2 alkyl groups; R14 is OH or OR12;
Rl5 is unsubstituted or substituted -(CH2)mAr where m is 0-2, or unsubstituted or substituted Ci-6 alkyl, wherein optional substituents comprise from one to three groups independently selected from the group consisting of -CH3 or -CH2CH3 unsubstituted or substituted by 1 or more halogens, -NO2, -Si(R4)3, -NRIQRH, -C(O)R4, -C(O)OR4, -OR4, -CN, -C(O)NRιoRl 1, -OC(O)NRioRl 1, -OC(O)Ri2, -NRιoC(O)NRιoRll, -NRιoC(O)Rn, -NRioC(O)ORi2, -NRi()C(O)Ri3, -C(NRιo)NRioRll, -C(NCN)NRlθRll, -C(NCN)SR9, -NRioC(NCN)SR9 , -NRiθC(NCN)NRlθRll, - RioS(O)2Rl2, -S(O)m'Rl2 where m' is 0-2, -NRiθC(O)C(O)NRioRll, -NRιoC(O)C(O)Rlθ, thiazolyl, imidazolyl, oxazolyl, pyrazolyl, triazolyl, and tetrazolyl;
AT is 2-, 3- or 4-pyridyl, pyrimidyl, pyridazyl, 2-imidazolyl, mo holino, or phenyl;
Xl is YR2, halogen, nitro, -NR4R5, or formyl amine;
X2 is O or NR4;
X3 is hydrogen or X\; Y is O, S, SO or SO2;
Z is O or NCN; provided that a) Z is NCN only when R3 is -NR4R5 or -S(CR4R5)nCH3; or b) when Xi is -NR4R5 or formyl amine, then Rl is not CH3 or C2H5 when X2 is O and X3 is H or halogen; or c) when R3 is CR4R5NR4R9, and X2 is O, and Rl is phenyl, then one of R6. R7, or R8 is other than H; or d) when Z is NCN, and X 1 is YR2, and Y is O, and R2 is CH3 and R3 is NH2, and R9 is H, OH, OCH3 or CH3, and R8 is H, and R6 and R7 are both hydrogen, or are hydrogen and methyl, hydrogen and CF3 or hydrogen and ethyl, and X2 is O, then Rl is not CF3, CF2H, or CF2CF2H; or e) when Z is NCN, and X is YR2» and Y is O, and R2 is CH3 and R3 is NH2, and R9 is H, OH, OCH3 or CH3, and R8 is H, and R6 and R7 are both hydrogen, or are hydrogen and methyl, hydrogen and CF3 or hydrogen and ethyl, and X2 is NR4 and R4 is CH3, then Ri is not CH3; or f) when Q is A, and X2 is O, Ri is aryl or halo-substituted aryl, R is halo or OR4, R7 is H, Rδ is CH3 or CH2F and R9 is H or C1.3a.kyl, then R15 is not lower alkyl, mono or dichlorosubstituted lower alkyl, or unsubstituted or subsitituted phenyl; or g) when Q is B, and X2 is O, Rj is aryl or halo-substituted aryl, R7 is H, Rg is CH3 or CH2F, R9 is H or C1.3a.kyl, then Rg is other than halo or OR4.
These compounds are useful in the mediation or inhibition of the enzymatic activity (or catalytic activity) of phosphodiesterase IV (PDE IV). The novel compounds of the Formula (I) also have Tumor Necrosis Factor (TNF) inhibitory activity.
This invention also relates to a composition, including a pharmaceutical composition, comprising a compound of the Formula I and a carrier or diluent
The invention also relates to a method of mediation or inhibition of the enzymatic activity (or catalytic activity) of phosphodiesterase IV, including mammals which comprises administering to a mammal in need thereof an effective amount of a compound of Formula I.
The invention further provides a method for treating allergic and inflammatory diseases which comprises administering to a mammal, including humans, in need thereof, an effective amount of a compound of the Formula I. The invention also provides a method for treating asthma which comprises administering to a mammal, including humans, in need thereof an effective amount of a compound of the Formula I.
This invention also relates to a method of inhibiting TNF production in a mammal, including humans, which method comprises administering to a mammal in need of such treatment an effective TNF inhibiting amount of a compound of the Formula (I). This method may be used for the prophylactic treatment or prevention of certain TNF mediated disease states amenable thereto.
This invention also relates to a method of treating a human afflicted with a human immunodeficiency virus (HIV), which comprises administering to such human an effective TNF inhibiting amount of a compound of the Formula (I).
The compounds of the Formula (I) are also useful in the treatment of additional viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo.
In yet a further aspect this invention covers a process for making a compound of formula I, which process comprises one or more of the following steps: a) forming a salt; b) treating an amine with a lower alkyl acylating agent to form the corresponding amide; c) treating an amine with biuret to form the corresponding imidodicarbamide; d) hydrolyzing the product of an amine treated with trimethylsilyl isocyanate to form the corresponding urea; e) treating an amine with cyanodithioiminiocarbonate to form the corresponding N^-cyano-S -methyl-N * -isothiouriedo; f) treating an N^-cyano-S-methyl-N*- isothiouriedo with an amine to form the corresponding N'-cyanocarboximidamide; g) treating a amine with a mixture comprising (4S )-2,2-dimethyl- 1 ,3- dioxolane-4-carboxylic acid and isobutyl chloroformate in the presence of an organic base to form the corresponding 2,3-dihydroxypropanamide and the corresponding carbamate; h) treating an amine with 4(R)-2^-dimethyl-l,3-dioxaolane-4-carboxylic acid to form the corresponding 2,2-dimethyl-l,3-dioxolane-4-carboxamide; i) treating an amine with trimethyl phosphonofoπnate to form the corresponding phosphonoformamide; j) reacting an amine with dimethoxyfoimylphosphonyl chloride; k) treating an aminopropionitrile with acetoacetyl chloride to form the corresponding 2-acetoxyacetamide;
1) hydrolyzing a protected aminoacetamide to form the corresponding 2- aminoacetamide; or m) treating an amine with a sulfonylating agent to form the corresponding sulfonamide.
Specific Embodiments
Specific embodiments of this invention are defined and illustrated below.
The following terms and phrases used herein are to be interpreted as having the meaning or meanings given hereafter. "Lower alkyl" means a group having 1 to 6 carbon atoms. This included normal, secondary and tertiary form where such forms can exist e.g., isopropyl, t-butyl and the like. Normal, or linear, radicals are preferred, especially methyl, ethyl, propyl, butyl, pentyl and hexyl. Halo means fluoro, chloro, bromo and iodo. The term "cycloalkyl" or "cycloalkyl alkyl" as used herein is meant to include those rings of 3-7 carbon atoms, such as cyclopropyl, cyclopropylmethyl, cyclopentyl or cyclohexyl. "Aryl", unless specified otherwise, means an aromatic ring or ring system of 6-10 carbon atoms such as phenyl. Preferably the aryl is monocyclic, i.e., phenyl. The alkyl chain is meant to include both straight or branched chain radicals of 1 to 4 carbon atoms. Some compounds of formula I may be sufficiently basic so as form acid addition salts. This work includes all such salts, particularly those which retain the activity of the parent base and are acceptable for pharmaceutical use. Making acid addition salts is a well know art and any documented procedure is expected to provide the desired product in the context of this invention. "Inhibiting the production of TNF" means, a) a decrease of excessive ia vivo TNF levels in a human to normal levels or below normal levels by inhibition of the in vivo release of TNF by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the translational or transcription level, of excessive in vivo TNF levels in a human to normal levels or below normal levels; or c) a down regulation, by inhibition of the direct synthesis of TNF as a postranslational event 'TNF mediated disease states" means all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL-1, or IL-6. A disease state in which IL-1, for instance is a major component and whose production or action is exacerbated or which is secreted in response to TNF, would therefore be considered a disease state mediated by TNF. "Cytokine" means any secreted polypeptide that affects the functions of other cells, and is a molecule which modulates interactions between cells in the immune or inflammatory response. A cytokine includes, but is not limited to monokines and lymphokines regardless of which cells produce them. For instance, a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte but many other cells produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epideral keratinocytes, and β-lymphocytes. Lymphokines are generally referred to as being produced by lymphocyte cells. Examples of cytokines for the present invention include, but are not limited to Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α) and Tumor Necrosis Factor beta (TNFβ). Some compounds of formula I may exist in two distinct enantiomeric forms. Some compounds of Formula I may exist in at least two distinct diasteriomeric forms possessing distinct physical and biological properties. Furthermore some compounds of Formula I may exist in a tautomeric form, such as the enol or enamine. All these forms are within the scope of this invention.
Preferred Rl groups are cyclopropylmethyl, cyclopentymethyl, cyclohexylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, tetτahydrofur-2-yl, cyclopentenyl, benzyl, or lower alkyl optionally substituted by 1 or more fluoro groups. When Ri is lower alkyl substituted by 1 or more halogens, the halogens are preferably fluorine and chlorine, more preferably a Ci-4 alkyl substituted by 1 or more fluoro groups, more preferably 1 or more times by fluorine. The most preferred halo substituted chain length is one or two carbons, and most preferred are the moieties -CF3, -CH2F, -CHF2, -CF2CHF2, -CH2CF3, and - CH2CHF2. Preferred Ri substitutents are cyclopentyl, cyclopropylmethyl, -CF3, and - CHF2.
When R 1 is a C7.11 polycycloalkyl, examples are bicyclo[2.2.1 ]-heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, tricyclo 5.2.1.02»6]decyl, additional examples of which are described in Saccamano et al., WO 87/06576, published 5 November 1987 which is incorporated herein by reference in its entirety.
Oxygen is the preferred X2 radical.
As for Xi, the preferred radical is YR2 where Y is oxygen. The preferred R2 group is a methyl or ethyl unsubstituted or substituted by 1 or more halogens. The preferred halogens are fluoro and chloro, most preferably fluoro. The more preferred R2 groups are methyl, -CF3, -CHF2, or -CH2CHF2 moiety. Most preferred are difluoromethyl and methyl.
Hydrogen is the referred X3 radical.
As regards the Q group, the preferred radicals are those which form an amide, sulfonamide, imidodicarbamide, urea, N^-cyano-S-methyl-NMso±iouriedo, 2,3- dihydroxypropanamide, 2,2-ctimethyl-l,3-dioxolane-4-carboxamide, 2-acetoxyacetamide, or a 2-aminoacetamide.
Preferred R6 moieties are H, C(O)NH2, C≡CR4, CN, C(O)H, CH2OH, CH2F, CF2H, and CF3. More preferred are C≡CH and CN. R7 is preferably H or CN. Rδ is preferably H, -C(O)NH2 or CN.
Preferred R9 moieties include hydrogen, optionally substituted -(CH2)0-2(2-, 3- or4-pyridyl), (CH2)l-2(2-imidazolyl), (CH2)2(4-morpholinyl), (CH2)2(4-piperazinyl), (CH2)l-2(2-thienyl), (CH2)l-2(4-thiazolyl), and (CH2)0-2phenyl.
Preferred rings when Rio and Ri 1 in the moiety -NRioRl 1 together with the nitrogen to which they are attached form a 5 to 7 membered ring optionally containing at least one additional heteroatom selected from O, N, or S include, but are not limited to 1- imidazolyl, 2-(R8)-l-imidazolyl, 1-pyrazolyl, 3-(R8)-l -pyrazolyl, 1-triazolyl, 2-triazolyl, 5-(R8)-l-triazolyl, 5-(R8)-2-triazolyl, 5-(R8)-l-tetrazolyl, 5-(R8)-2-tetrazolyl, 1- tetrazolyl, 2-tetrazloyl, morpholinyl, piperazinyl, 4-(R8)-l-piperazinyl, or pyrrolyl ring. Preferred R15 moieties include, optionally substituted Ci-3alkyl, -(CH2)0-2(2-,
3- or 4-pyridyl), (CH2)l-2(2-imidazolyl), (CH2)2(4-morpholinyl), (CH2)2(4-piperazinyl), (CH2)l-2(2-thienyl), (CH2)l-2(4-thiazolyl), and (CH2)0-2phenyl.
Preferred rings for R13 include (2-, 4- or 5-imidazolyl), (3-, 4- or 5-pyrazolyl), (4- or 5-triazolyl[l,2,3]), (3- or 5-triazolyl[ 1,2,4]), (5-tetrazolyl), (2-, 4- or 5-oxazolyl), (3-, 4- or 5-isoxazolyl), (3- or 5-oxadiazolyl[ 1,2,4]), (2-oxadiazolyl[ 1,3,4]),
(2-thiadiazolyl[ 1,3,4]), (2-, 4-, or 5-thiazolyl), (2-, 4-, or 5-oxazolidinyl), (2-, 4-, or 5-thiazolidinyl), or (2-, 4-, or 5-imidazolidinyl). Preferred are those compounds of formula (I) wherein R is -CH2-cyclopropyl, -
CH2-C5-6 cycloalkyl, -C4-6 cycloalkyl, tetrahydrofuran-3-yl, (3- or 4-cyclopentenyl), benzyl, and -Ci-2 alkyl optionally substituted by 1 or more fluorines; R2 is methyl or fluoro-substituted alkyl; R6 is CN or C≡CR4; and X is YR2- Most preferred are those compounds wherein Ri is -CH2-cyclopropyl, cyclopentyl, or CF2H; Rg is CN or C≡CH; X is YR2; Y is oxygen; X2 is oxygen; X3 is hydrogen; and R2 is CF2H or methyl.
Phosphodiesterase TV inhibitors are useful in the treatment of a variety of allergic and inflammatory diseases including: asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, inflammatory bowel disease states including Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome. In addition, PDE TV inhibitors are useful in treating diabetes insipidus, (Kidnev Int. 37:362, 1990; Kidnev Int. 35:494, 1989) and central nervous system disorders such as depression and multi-infarct dementia.
Compounds of Formula I are useful in treating, prophylactically or therapeutically, disease states in humans which are exacerbated or caused by excessive or unregulated
TNF production. Therefore, the present invention also provides a method for inhibiting the production of tumor necrosis factor (TNF) in an animal in need thereof, including humans, which method comprises administering to said animal an effective amount of a compound of formula I alone or mixed with a carrier.
Compounds of the Formula I may be administered systemically, topically, parenterally or by inhalation in conventional dosage forms prepared by combining such agent with standard carriers according to conventional procedures in an amount sufficient to produce the desired therapeutic activity for treatment of a TNF-mediated disease state or for use as a PDE TV inhibitor.
The daily dosage regimen, based on oral administration, is suitably about .001 mg/kg to lOOmg/kg, preferably 0.01 mg Kg to 40 mg/Kg, of a compound of the Formula I or a pharmaceutically acceptable salt thereof calculated as the free base. The active ingredient may be administered from 1 to 6 times a day, sufficient to exhibit activity.
Other doseage regimens may require more or less compound depending on the route by which they are administered, by the enchancing or retarding affects of excipients, to name two factors which can influence the dosage regimen. But optimizing a dosage regimen is within the scope of a person skilled in the art and can be deteraiined by following well established techniques for deteπnining what may constitute an effective amount to compound in a given situation. The amount of a compound of the formula I required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the condition and the animal undergoing treatment, and is ultimately at the discretion of the one directing the use of these compounds. While it is possible for an active ingredient to be administered alone as the raw chemical, it is preferable to present it via a vehicle of some sort Appropriate forms for using these compounds may be prepared by conventional techniques. For pharmaceutical or veterinary use, a composition of the present invention will comprising an effective, non-toxic amount of a compound of the formula I and a pharmaceutically acceptable carrier or diluent The carriers) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious in the intended use. Preferably the composition is in unit dosage form, for example a tablet capsule or metered aerosol dose, so that the patient may self-administer a single dose.
By systemic administration is meant oral, intravenous, intraperitoneal, topical, inhalation and intramuscular administration. By topical administration is meant non- systemic administration and includes the application of a compound externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the compound does not significantly enter the blood stream. The term parenteral' as used herein includes intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred.
For oral administration each dosage unit may contains from 1 mg to 100 mg, and preferably from 10 mg to 30 mg of a compound of the formula I or a pharmaceutically acceptable salt thereof calculated as the free base. Appropriate dosage forms for inhalation include an aerosol formulation or a metered dose inhaler. The daily dosage regimen for a compound of the Formula (I) for intranasal administration and oral inhalation is suitably about 10 to about 1200 mg. As for topical use , a suitable dose of a TNF production inhibiting compound of the formula I is from about 0.01 mg to about 100 mg of base for topical administration, the most preferred dosage being about 0.01 mg to about 30 mg, for example, 0.003 mg to 10 mg administered two or three times daily. Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. No unacceptable toxicological effects are expected when these compounds are administered in accordance with the present invention. Synthetic Methods
Compounds of Formula I can be prepared by one of skill in the art according to the procedures outlined in the Examples, infra. The preparation of any remaining compounds of the Formula I not described therein may be prepared by the analogous processes disclosed herein.
In general an amine is first prepared, that is a compound where R is NH2, and then this intermediate is converted to the desired target compound by one or more steps, all of which are described below. These amines can be prepared by the methods set out in PCT/US91/04795; those processes and the amines disclosed there are incorporated herein by reference to the extent that information is necessary or useful for understanding how to make the amine precursors used in this work. By way of illustration, a benzaldehyde of formula (a)
Figure imgf000014_0001
is reacted with nitromethane in a suitable solvent such as acetic acid with a catalyst at between about 80 - 100°C or using the conditions of Shales, et al., J. Amer. Chem. Soc, 74, 4486 (1952) to provide the alkenylnitrate of formula (b).
Figure imgf000014_0002
Treating formula b with a reducing agent such as lithium aluminum anhydride or hydrogen with a heavy metal catalyst and an acid yields the corresponding amine.
Alternatively, the aldehyde of formula a can be treated with a lithium halide and a silyl halide in an appropriate solvent followed by a reducing agent e.g., siloxane, providing a halide of formula (c)
Figure imgf000014_0003
where X4 is the halogen derived from the lithium halide. Cyanide is then used to displace the halide. This nitrile is then reduced, for example by hydrogen and suitable heavy metal catalyst such as nickel with ammonia or palladium on carbon with an acid such as perchloric acid to obtain the primary amine.
Where R6 is nitrile, such compounds can be prepared by dehydrating a compound of formula (d)
Figure imgf000015_0001
using a reagent such as trifluoroacetic anhydride. This converts the amide to the nitrile and subsequently the Boc group is hydrolized, providing the primary amine. Alternative protecting groups can be used. See for example those disclosed in Greene, L, Protective Groups in Organic Synthesis, Wiley Publishers, NY (USA) (1981). Methods for making this compound are described in PCT/US91/04795, the publication noted above.
Converting the primary amines to compounds of formula I is illustrated in the Examples set out below. These chemistries, and analogous processes, will make all of the compounds of formula I.
Assay Methods
The assay(s) used to confirm the PDE IV antagonistic activity of these compounds can be found in patent application PCT/US91/04795 (International Publication No. WO 92/00968) published 23 January 1992. That information is incorporate herein by reference. The compounds of formula I have exhibited activity at levels consistent with those believed to be useful in treating PDE TV related disease states in those assays. The following Examples are given to illustrate how to make compounds of formula I and formulations and testing processes for confirming their activity. These are only examples and are not intended to limit the invention in any fashion or with regards to its scope.
Examples
Example 1
2-(3-Cvclopentvloxv-4-methoxvphenvnethvlamine la. 3-Cyclopentyloxy-4-methoxybenzaIdehyde A mixture of 3-hydroxy-4-methoxy- benzaldehyde (40 g, 0.26 mol), potassium carbonate (40 g, 0.29 mol) and bromocyclopentane (32 mL, 0.30 mol) in dimethylformamide (0.25 L) was heated under an argon atmosphere at 100°C. After 4h, additional bromocyclopentane (8 mL, 0.07 mol) was added and heating was continued for 4h. The mixture was allowed to cool and was filtered. The filtrate was concentrated under reduced pressure and the residue was partitioned between ether and aqueous sodium carbonate. The organic extract was washed with aqueous sodium carbonate and dried (potassium carbonate). The solvent was removed in vac o and the residue was purified by flash chromatography, eluting with 2: 1 hexanes ether, to provide a pale yellow oil.
Analysis Calc. for C13H16O3: C 70.89, H 7.32; found: C 70.71, H 7.33.
lb; 3-Cvclopentyloxy-4-methoxy-β-nitrostyrene To a solution of 3-cyclopentyloxy-4- methoxybenzaldehyde (6.04 g, 27.4 mmol) in glacial acetic acid (36 mL) under an argon atmosphere was added nitromethane (7.35 mL, 136.0 mmol) and ammonium acetate (3.15 g, 40.9 mmol). The resulting mixture was heated at reflux for 3h, then allowed to cool to room temperature. The mixture was poured into water and extracted twice with methylene chloride. The combined organic extracts were washed successively with aqueous sodium bicarbonate and water and dried (potassium carbonate). Removal of the solvent in vacuo and purification of the residue by flash chromatography, eluting with 1 : 1 methylene chloride/hexanes, provided the nitrostyrene as a bright yellow solid: m.p. 133- 134°C.
Analysis Calc. for C14H17NO4 : C 63.87, H 6.51, N 5.32; found: C 64.08, H 6.42, N 5.33.
lc. 2-(3-Ovclopentvloxv-4-methoxvphenvl>)ethvlaπ-ine. To a suspension of lithium aluminum hydride (10.8 g, 28.5 mmol) in ether (250 mL) at 0°C under an argon atmosphere was added dropwise a solution of 3-cyclopentyloxy-4-methoxy-β-nitrostyrene (15 g, 57.0 mmol) in tetrahydrofuran (85 mL). The resulting mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was cooled to 0°C and quenched by the successive dropwise addition of water (11 mL), 15% sodium hydroxide (11 mL) and water (33 mL). The mixture was filtered through a pad of Celite and the filtrate was washed successively with water, 10% hydrochloric acid and water. The aqueous washes were combined, made basic with saturated aqueous potassium carbonate and extracted three times with ether and twice with methylene chloride. The organic layers were combined and dried (potassium carbonate). Removal of the solvent in vacuo provided the amine. A portion of the crude amine was purified by flash chromatography, eluting with 1:10:90 water/methanol/chloroform. Analysis Calc. for C14H21NO25/8 H2O: C 68.19, H 9.09, N 5.68; found: C 68.39, H 9.16, N 5.85 Example 2 N-r2-(3-Cvc1opentvloxv-4-methoxvphenvttethvl1acetamide To a solution of crude 2-(3-cyclopentyloxy-4-methoxyphenyl)ethylamine (0.5 g, 2.1 mmol) in pyridine (1.8 mL) under an argon atmosphere was added acetic anhydride (1.25 mL). The resulting solution was stirred at room temperature for 16h and then concentrated under reduced pressure. The residue was dissolved in methylene chloride, washed with water and dried (sodium sulfate). The solvent was removed in vacuo, the residue was purified by flash chromatography, eluting with 4% methanol/ether, and then triturated with ether to provide the acetamide : m.p. 87-88°C.
Analysis Calc. for C16H23NO3: C 69.29, H 8.36, N 5.05; found: C 69.11, H 8.17, N 5.00.
Example 3
N-r2-f3-Cvclopen vloxy-4-methoxyphenvnethvnmethanesulfonamide To a solution of crude 2-(3-cyclopentyloxy-4-methoxyphenyl)ethylamine (0.25 g,
1.1 mmol) in methylene chloride (2 mL) at 0°C under an argon atmosphere was added triethylamine (0.2 mL, 1.43 mmol) and methanesulfonyl chloride (0.106 mL, 1.37 mmol). The resulting solution was stirred at room temperature for 16h, diluted with methylene chloride, washed with water and dried (magnesium sulfate). The solvent was removed in vacuo, the residue was purified twice by flash chromatography, eluting with 1 :2 hexane/ether, to provide an oil.. MS (DCI, CH4) m/e 313 (M ' ).
Example 4 Dimethyl N-r2-f3-cvclopentvloxv-4-methoxvphenvnethvnphosphonoformamide A mixture of trimethyl phosphonoformate (0.27 mL, 2.0 mmol) and 2-(3- cyclopentyloxy-4-methoxyphenyl)ethylamine (0.47 g, 2.0 mmol) was allowed to stand under an argon atmosphere for 3h. During this time, the mixture was sonicated twice for 3 min. The mixture was dissolved in methylene chloride and washed successively with 10% hydrochloric acid and water and dried (potassium carbonate). The solvent was removed in vacuo and the residue was purified by two successive flash chromatographies, eluting first with 1.5:98.5 methanol/ methylene chloride and subsequently with 75:25 ethyl acetate/ hexanes, to provide the phosphonoformamide.
Analysis Calc. for Ci7H26NO6P-3/4 H2O: C 53.04, H 7.20, N 3.64, P 8.05; found: C 52.94, H 6.92, N 3.61, P 8.15. Example 5 N-r2-(3-Cvclonentvloxv-3-methoxvphenvnethvnimidodicarbamide
A solution of 2-(3-cyclopentyloxy-4-methoxyphenyl)ethylamine (0.24 g, 1.0 mmol) and biuret (0.52 g, 5.0 mmol) in dimethylformamide (6 mL) under an argon atmosphere was heated to 110°C for 3h. The reaction mixture was allowed to cool to room temperature and was concentrated under reduced pressure. The residue was partitioned between methylene chloride and water, and the organic extract was dried
(magnesium sulfate). The solvent was removed in vacuo and the residue was purified by flash chromatography, eluting first with 10% ethyl acetate/methylene chloride and then with 4% methanol/methylene chloride. An off-white solid was obtained, which was further purified by flash chromatography, eluting with 2.5% methanol/methylene chloride, to provide an oil.
Analysis Calc. for C16H23N3O4 I/2 H2O: C 58.16, H 7.32, N 12.69; found: C 58.34, H 7.12, N 12.72.
Example 6
Dimethyl N-r2-f3-cvclopentvloxv-4-methoxvphenvnethvlaminolphosDhonoformate To phosphorus pentachloride (0.42 g, 2.0 mmol) was added trimethyl phosphonoformate (0.27 mL, 2.0 mmol) and the resulting mixture was stirred at room temperature under an argon atmosphere for 4h. The mixture was concentrated under reduced pressure, dissolved in tetrahydrofuran (2 mL) and added to a -78°C solution containing 2-(3-cyclopentyloxy-4-methoxyphenyl)ethylamine (0.48 g, 2.0 mmol) and diisopropylethylamine (0.39 mL, 2.2 mmol) in tetrahydrofuran (3 mL) under an argon atmosphere. The reaction mixture was stirred for 1.5h at -78°C and quenched by the addition of ammonium chloride. The solvent was removed under reduced pressure, and the residue was partitioned between dilute aqueous hydrochloric acid and methylene chloride. The organic extract was washed with water and dried (potassium carbonate). The solvent was removed in vacuo and the residue was purified by two successive flash chromatographies, eluting first with 2.5:50:50 methanol/methylene chloride/hexanes and subsequently with 15: 85 ethyl acetate/methylene chloride, to provide the phosphonoformate.
Analysis Calc. for Ci7H26NO6P-l/3 H2O: C 54.11, H 7.12, N 3.71, P 8.21; found: C 54.21, H 7.20, N 3.82, P 8.24.
Example 7 N-r2-f3-Cvclopentvloxv-4-methoxvphenvnethvllurea
To a solution of 2-(3-cyclopentyloxy-4-methoxyphenyl)ethylamine (0.47 g, 2.0 mmol) in tetrahydrofuran (10 mL) under an argon atmosphere was added trimethylsilyl isocyanate (0.42 mL, 3.1 mmol). The resulting mixture was heated at reflux for lh, was allowed to cool to room temperature and then was stirred overnight The reaction mixture was again heated to reflux for an additional 5h and allowed to cool to room temperature. Ammonium chloride was added, and the mixture was concentrated under reduced pressure. The residue was partitioned between methylene chloride and water. The organic extract was washed successively with 10% hydrochloric acid and water and dried (potωsium carbonate). Removal of the solvent in vacuo and purification of the residue by flash chromatography, eluting with 3% methanol/methylene chloride, provided the urea as a white solid: m.p. 136-37°C. Analysis Calc. for C15H22N2O3: C 64.73, H 7.97, N 10.06; found: C 64.66, H 7.97, N 10.28. Example 8 l-(N2-Cvano-S-methvl-N.LisothiouriedoV2-f3-cvclopentvloxv-4-methoxvphenvnethane
To a solution of 2-(3-cyclopentyloxy-4-methoxyphenyl)ethylamine (0.31 g, 1.31 mmol) in dry pyridine (5 mL) under an argon atmosphere was added dimethyl N- cyanodithioiminocarbonate (0.37 g, 2.56 mmol). The resulting mixture was heated at reflux for 3h, then allowed to cool to room temperature and concentrated under reduced pressure. The residue was dissolved in methylene chloride and washed successively with dilute aqueous hydrochloric acid and water and dried (potassium carbonate). The solvent was removed in vacuo and the residue was purified by flash chromatography, eluting with 4:6 ethyl acetate/hexanes, to provide a white solid : m.p. 112-113°C. Analysis Calc. for C17H23N3O2S I/3 H2O: C 60.15, H 7.03, N 12.38, S 9.44; found: C 60.02, H 6.93, N 12.55, S 9.26.
Example 9 N'-Cvano-l-r2-(3-cvclopentvloxv-4-methoxvphenvnethvncarboximidamide A solution of l-(N2-cyano-S-methyl-N1-isothiouriedo)-2-(3-cyclopentyloxy-4- methoxyphenyl)ethane (0.22 g, 0.67 mmol) in tetrahydrofuran (4 mL) was added to a suspension of sodium hydride (80% dispersion, 0.027 g, 0.9 mmol) in tetrahydrofuran (2.5 mL) at room temperature under an argon atmosphere. After 2h, the mixture was heated to 50°C for 2h, was cooled to room temperature, was treated with di-t- butyldicarbonate (0.29 g, 1.34 mmol) and was allowed to stir at room temperature overnight The mixture was quenched with ammonium chloride, was diluted with methylene chloride, was washed successively with dilute sodium bicarbonate, dilute hydrochloric acid and then was dried (potassium carbonate). The solvent was evaporated and the residue was purified by flash chromatography, eluting with 15% ethyl acetate/hexanes, to provide an oil (0.19 g, 69%). This oil was placed in liquid ammonia at -45°C, the mixture was stirred for 8h and the ammonia was allowed to evaporate overnight at room temperature. The residue was dissolved in methylene chloride (2 mL) at 0°C under an argon atmosphere and treated with trifluoroacetic acic (0.5 mL). After 45 min, solid sodium bicarbonate was added, the mixture was diluted with methylene chloride, the organic layer was washed with 5% aqueous sodium bicarbonate and then with water. The organic extract was dried (potassium carbonate) and evaporated. The residue was purified by flash chromatography, eluting with 3-20% isopropanol/methylene chloride, to provide a solid: m.p. 53-55°C. Analysis Calc. for Ci6H22N O2-3/4 H2O: C 60.84, H 7.50, N 17.74; found: C 60.70, H 7.07, N 17.35.
Example 10 N-r2-r3-Cvclopentvloxv-4-methoxvphenvnethvnacetamide 10a. N-(t-ButoxvcarbonvlV2-r3-cvclopentvloxv-4-methoxvphenvnethvlamine A solution of 2-(3-cyclopentyloxy-4-methoxyphenyl)ethylamine (2.5 g, 10.6 mmol) in methylene chloride (25 mL) was treated with t-butyloxycarbonylanhydride (2.5 mL, 11 mmol) and stirred under an argon atmosphere for 2h. The solvent was removed in vacuo and the residue was purified by flash chromatography, eluting with 1:1 ether/hexanes, to provide a colorless oil. 10b. N-ft-ButoxvcarbonvlV2-f3-cvclopentvloxv-4-methoxvphenvn-N- methylethylamine A solution of N-(t-butoxycarbonyl)-2-(3-cyclopentyloxy-4- memoxyphenyl)ethylamine (1.2 g, 3.6 mmol) in dimethylfoπiiamide (10 mL) was treated with sodium hydride (0.12 g of 80% dispersion, 4 mmol) and stirred at room temperature under an argon atmophere for 2h. Methyl iodide (0.3 mL, 4.8 mmol) was added and stirring was continued for another 3h. The solvent was removed in vacuo and the residue was partitioned between methylene chloride and acidic water. The organic layer was dried (potassium carbonate) and evaporated. Purification by flash chromatography, eluting with 3:1 hexanes ether, provided an oil. 10c. 2-π-cvclopentvloxv-4-methoxvphenvn-N-methvlethvlamine A solution of N-(t- butoxycarbonyl)-2-(3-cyclopentyloxy-4-methoxyphenyl)-N-meώylethylamine (0.65 g, 1.86 mmol) in methylene chloride (5 mL) was treated with trifluoroacetic acid (2 mL) and stirred under an argon atmosphere for lh. The solvent was removed in vacuo and the residue was partitioned between methylene chloride and 5% sodium bicarbonate. The organic layer was dried (potassium carbonate) and evpaorated to an oil . lOd. N-r2-f3-Cvclopentvloxv-4-methoxvphenvnethvllacetamide A solution of 2-(3- cyclopentyloxy-4-methoxyphenyl)-N-methylethylamine (0.12 g, 0.48 mmol) in pyridine (0.4 mL) and acetic anhydride (0.28 mL) was stirred at room temperature under an argon atmosphere for 24h. The liquids were evaporated and the residue was purified by flash chromatography, eluting with 97:3 chloroform/methanol, to provide an oil. Analysis Calc. for C17H25NO30I/4H2O: C 69.01, H 8.69, N 4.73; found: C 68.81, H 8.70, N 4.58.
Example 11 N-r2-f3-CvclθDentvloxv-4-methoxvphenvnethvn-2-hvdroxvacetamide
A solution of 3-cyclopentyloxy-4-methoxyphenethylamine (0.1 g, 0.42 mmol) in tetrahydrofuran (3 mL) was cooled to 0°C and was treated with triethylamine (0.064 mL, 0.46 mmol) and benzyloxyacetyl chloride (0.066 mL, 0.42 mmol). The reaction was stirred under an argon atmosphere for 0.5h, then was partitioned between methylene chloride and acidic water. The extract was dried (potassium carbonate) and evaporated. The resulting solid (0.16 g) was dissolved in ethanol, a small amount of 10% palladium on carbon was added, the resulting mixture was hydrogenated at 50 psi for 24h, then filtered through a pad of Celite and evaporated. Purification by flash chromatography, eluting with 5% methanol/chloroform, provided a solid: m.p. 69.5-71°C. Analysis Calc. for C16H23NO4 I/8 H2O: C 65.01, H 7.93, N 4.74 ; found: C 65.03, H 7.83, N 4.83.
Example 12 N-r2-r3-Cvclopentvloxv-4-methoxvphenvnethvn-2-methoxvacetamide A solution of 3-cyclopentyloxy-4-methoxyphenethylamine (0.2 g, 0.85 mmol) in tetrahydrofuran (6 mL) was cooled to 0°C and was treated with triethylamine (0.13 mL, 0.92 mmol) and methoxyacetyl chloride (0.078 mL, 0.85 mmol). The reaction was stirred under an argon atmosphere for 0.25h, then was partitioned between methylene chloride and water. The extract was dried (potassium carbonate) and evaporated. Purification by flash chromatography, eluting with 5% methanol/chloroform, provided an oil ; additional 0.1 g of impure product also obtained).
Analysis Calc. for C17H25NO4: C 66.43, H 8.20, N 4.56 ; found: C 66.67, H 8.18, N 4.45.
Example 13
N-r2-Cvano-2-f3-cvclopentvloxv-4-methoxvphenvnethvn-2-hvdroxvacetamide 13a. α-Bromo-3-cyclopentyloxy-4-methoxytoluene To 3-cyclopentyloxy-4- methoxybenzaldehyde (5.0 g, 22.7 mmol) was added lithium bromide (3.94 g, 45.4 mmol) and acetonitrile (25 mL). Upon dissolution, the reaction mixture was cooled to 0°C. Trimethylsilyl chloride (4.32 mL, 34.0 mmol) was slowly added and the reaction mixture was allowed to warm to room temperature and stirred for 15 min. The reaction mixture was again cooled to 0°C and 1,1,3,3-tetramethyldisiloxane (6.68 mL, 34.0 mmol) was added dropwise. The resulting mixture was allowed to warm to room temperature. After stirring for 2h, the mixture was separated into two layers. The lower layer was removed, diluted with methylene chloride and filtered. The filtrate was concentrated under reduced pressure, dissolved in methylene chloride and filtered. The solvent was removed in vacuo to provide a light tan oil, which was used without further purification. 13b. f3-CvcloDentvloxv-4-methoxvphenvnacetonitrile To a solution of α-bromo-3- cyclopentyloxy-4-methoxytoluene (6.6 g, 23.0 mmol) in di_methylformamide (10 mL) under an argon atmosphere was added a suspension of powdered sodium cyanide (2.5 g, 51.0 mmol) in dimethylformamide (40 mL). The resulting mixture was stirred at room temperature for 24h, then poured into cold water (250 mL) and extracted three times with ether/ethyl acetate. The combined organic extracts were washed three times with water and dried (sodium sulfate). The solvent was removed in vacuo and the residue was purified by flash chromatography, eluting with 30% ethyl acetate/hexanes, to provide a pale yellow oil .
13c. Methyl 2-cyano-2-(3-cyclopentyloxy-4-methoxyphenyl')acetate. To a suspension of sodium hydride (0.69 g of an 80% suspension in mineral oil washed three times with pentane, 22.44 mmol) in toluene (25 mL) under an argon atmosphere was added a solution of freshly distilled dimethyl carbonate (1.30 mL, 15.1 mmol) and (3- cyclopentyloxy-4-methoxyphenyl)acetonitrile (1.71 g, 7.44 mmol) in toluene (5 mL). The resulting mixture was heated at reflux for 1.25h, with most of the solvent then removed by distillation, and the remainder was stirred overnight at room temperature. The mixture was cooled to 0°C, partitioned between ice water and ether, and acidified. The product was extracted with ether, the extract was dried (sodium sulfate) and the solvent was removed in vacuo to provide an oil.
13d. 2-Cyano-2-(3-cyclopentyloxy-4-methoxyphenyl')acetamide A solution of methyl 2-cyano-2-(3-cyclopentyloxy-4-methoxyphenyl)acetate (2.1 g, 7.26 mmol) in concentrated ammonium hydroxide (50 mL) was stirred at room temperature for four days. A thick white precipitate formed after the first half hour. The reaction was cooled to 0°C, acidified to pH 2-3 with 10% aqueous hydrochloric acid, extracted three times with methylene chloride/methanol and dried (magnesium sulfate). The solvent was removed in vacuo to provide an off- white solid: m.p. 160-162°C. 13e. 3-(t-ButoxvcarbonvlaminoV2-f3-cvclopentvloxv-4-methoxvphenvnpropioamide To a solution of 2-cyano-2-(3-cyclopentyloxy-4-methoxyphenyl)acetamide (0.504 g, 1.85 mmol) in methanol (25 mL) was added 70% perchloric acid (0.18 mL, 1.9 mmol) and 10% palladium on carbon (0.03 g). The resulting mixture was hydrogenated at 50 psi for 2h and filtered through a pad of Celite. The filtrate was concentrated in vacuo. The solid residue was partitioned between methylene chloride and aqueous sodium carbonate and the organic layer was dried (sodium sulfate). The solvent was removed in vacuo, and the residue was dissolved in methylene chloride (25 mL) and treated with di-t- butyldicarbonate (0.5 mL, 2.18 mmol). After 20h, the solvent was evaporated and the residue was purified by flash chromatography, eluting with 1:1 ethyl acetate/hexanes, to provide a pale yellow solid.
13f. 3-(t-Butoxvcarrx)nvl_ιminoV2-(3-cvclopentvloxv-4-methoxvphenvnpropionitrile A solution of 3-(t-butoxycarbony___u_αino)-2-(3-cyclopentyloxy-4- methoxyphenyl)propioamide (0.29 g, 0.75 mmol) in dry tetrahydrofuran (5 mL) was treated with pyridine (0.135 mL, 1.66 mmol) and with trifluoroacetic anhydride (0.12 mL, 0.83 mmol) dropwise. The reaction was stirred at room temperature for 1.5h, then quenched with ice and partitioned between methylene chloride and water. The organic extract was dried (magnesium sulfate) and concentrated. Purification by flash chromatography, eluting with 3:7 ethyl acetate/hexanes, provided an orange-yellow oil. 13g. 3-Amino-2-(3-cyclopentyloxy-4-methoxyphenyl1propionitrile A solution of 3-(t- butoxycarbonylamino)-2-(3-cyclopentyloxy-4-methoxyphenyl)propionitrile (0.26 g, 0.71 mmol) in methylene chloride (5 mL) cooled to 0°C was treated with the dropwise addition of trifluoroacetic acid (1.0 mL) and stirred under argon for 2h at 0°C and 2h at room temperature. The reaction was neutralized with solid sodium bicarbonate, diluted with methylene chloride and washed with aqueous sodium bicarbonate and then with water. The organic extract was dried (potassium carbonate) and evaporated to provide a yellow oil . 13h. N-r2-Cvano-2-f3-cvclopentvloxv-4-methoxvphenvnethvn-2-acetoxvacetamide A solution of 3-amino-2-(3-cyclopentyloxy-4-methoxyphenyl)propionitrile (0.095 g, 0.36 mmol) in methylene chloride (2 mL) was cooled to 0°C and was treated with methylamine (0.057 mL, 0.43 mmol) and acetoacetyl chloride (0.045 mL, 0.4 mmol). The reaction was stirred under an argon atmosphere for 1.5h, then was treated with aqueous ammonium chloride and was extracted three times with methylene chloride. The extract was dried (magnesium sulfate) and evaporated. Purification by flash chromatography, eluting with 1:4 ethyl acetate methylene chloride, provided a colorless oil.
13i. N-r2-Cyano-2-(3-cyclopentyloxy-4-methoxyphenvDethyll-2-hvdroxyacetamide A solution of N-[2-cyano-2-(3-cyclopentyloxy-4-methoxyphenyl)ethyl]-2-acetoxyacetamide (0.102 g, 0.28 mmol) in methanol (5 mL) was treated with powdered potassium carbonate (0.096 g, 0.69 mmol) and stirred for 15 min. The mixture was diluted with water, was extracted three times with methylene chloride and the organic extract was dried (potassium carbonate) and evaporated. Purification by flash chromatography, eluting with 3% methanol/methylene chloride, provided an oil. Analysis Calc. for CπH22N2θ4-l/4 H2O: C 63.24, H 7.02, N 8.68 ; found: C 63.44, H 6.85, N 8.52. Example 14 N-r2-Cvano-2-r3-cvclopentvloxv-4-methoxvphenvnethvnurea To a solution of 2-cyano-2-(3-cyclopentyloxy-4-methoxyphenyl)ethylamine [3- amino-2-(3-cyclopentyloxy-4-methoxyphenyl)propionitrile, 0.17 g, 0.66 mmol] in tetrahydrofuran (5 mL) under an argon atmosphere was added trimethylsilyl isocyanate (0.13 mL, 0.96 mmol). The resulting mixture was stirred overnight at room temperature. Aqueous ammonium chloride was added, the mixture was extracted three times with 5% methanol/methylene chloride, the extract was dried (potassium carbonate) and evaporated. Purification of the residue by flash chromatography, eluting with 4% methanol/methylene chloride, provided the urea as a white solid: m.p. 55-61°C (sublimes). Analysis Calc. for Ci6H2ιN3θ3-l/4H2θ: C 62.42, H 7.03, N 13.65; found: C 62.35, H 6.75, N 13.54.
Example 15 N-r2-(3-Cvclopentvloxv-4-methoxvphenvnethvll-2-aminoacetamide
15a. N-r2-(3-Cvclopentvloxv-4-methoxvphenvnethvl1-2-t-butvloxvcarbonvlamino- acetamide A solution of 3-cyclopentyloxy-4-methoxyphenethylamine (0.32 g, 1.37 mmol) in methylene chloride (5 mL) at room temperature under an argon atmosphere was treated with triethylamine (0.19 mL, 1.37 mmol), N,N-dimethylaminopyridine (0.17 g, 1.37 mmol) and N-t-butyloxycarbonylglycine-N-hydroxysuccinimide ester (0.37 g, 1.37 mmol). The reaction was stirred for 2.5h, then was partitioned between methylene chloride and acidic water and extracted twice. The extract was dried (potassium carbonate) and evaporated. The crude product was combined with that of a similar reaction conducted on the phenethylamine (0.03 g, 0.13 mmol) and was purified by flash chromatography, eluting with 5% methanol/chloroform, to provide an oil.
Analysis Calc. for C21H32N2O5 I/4 H2O: C 63.53, H 8.25, N 7.06; found: C 63.43, H
7.89, N 7.06.
15b. N-r2-f3-cvclopentvloxv-4-methoxvphenvnethvn-2-aminoacetamide A solution of
N-[2-(3-cyclopentyloxy-4-memoxyphenyl)ethyl]-2-t-butyloxycarrx)nylam__noacetamide (0.53 g, 1.35 mmol) in methylene chloride (16 mL) cooled to 0° C was treated with the dropwise addition of trifluoroacetic acid (1.7 mL), was allowed to come to room temperature and was stirred for 2.5h. The liquids were evaporated, the residue was partitioned between methylene chloride and saturated aqueous sodium bicarbonate and was extracted three times. The organic extract was dried (potassium carbonate) and evaporated. Purification by flash chromatography, eluting with 5% methanol/chloroform, provided a solid: m.p. 57-60° C. Analysis Calc. for C16H24N2O3: C 65.73, H 8.27, N 9.58 ; found: C 65.39, H 8.27, N 9.18. Example 16 f4RVN-r2-(3-Cvclopentvloxv-4-methoxvphenvl>>ethvll-2.2-dimethvl-L3-dioxόlane-4- carboxamide 16a. (4RV2.2-dimethvl-l .3-dioxolane-4-carboxvlic acid To a solution of methyl (4RV 2.2-dimethyl-l,3-dioxolane-4-carboxylate (2.21 g, 13.7 mmol) in methanol (60 mL) under an argon atmosphere was added lithium hydroxide monohydrate (0.61 g, 14.5 mmol). After stirring at room temperature for 3h, the reaction mixture was concentrated under reduced pressure. The residue was acidified with 10% HC1 and extracted with methylene chloride. The organic extract was washed with water and dried (magnesium sulfate). The solvent was removed in vacuo to provide the acid , which was used without further purification.
16b. f4RVN-r2-f3-Cvclopentvloxv-4-methoxyphenvnethvn-2.2-dimethvl-l.3- dioxolane-4-carboxamide To a solution of (4R)-2^-dimethyl-l,3-dioxolane-4-carboxylic acid (0.50 g, 3.42 mmol) in 1,2-dimethoxyethane (10 mL) under an argon atmosphere was added N-methylmorpholine (0.44 mL, 3.93 mmol) and ethyl chloroformate (0.38 mL, 3.93 mmol). The resulting mixture was stirred at room temperature for 4h, at which time was added a solution of 2-(3-cyclopentyloxy-4-memoxyphenyl)ethylamine (0.75 g, 3.19 mmol) in 1,2-dimethoxyethane (5 mL). After stirring for 2h at room temperature, the mixture was concentrated under reduced pressure. The residue was dissolved in methylene chloride and washed successively with 10% HC1 (twice), aqueous sodium bicarbonate and water and dried (potassium carbonate). The solvent was removed in vacuo and the residue was purified by flash chromatography, eluting with 35% ethyl acetate/hexanes, to provide the carboxamide as a pale yellow oil. Analysis Calc. for C20H29NO5 I/2 H2O: C 64.50, H 8.12, N 3.76; found: C 64.68, H 7.84, N 3.86. Example 17 f2RVN-r2-f3-Cvclopentyloxy-4-methoxyphenvnethvll-2.3-dihvdroxvpropanamide To a solution of (4R)-N-[2-(3-cyclopentyloxy-4-methoxyphenyl)ethyl]-2,2- di_methyl-l,3-dioxolane-4-carboxamide (0.48 g, 1.32 mmol) in tetrahydrofuran (2.5 mL) under an argon atmosphere was added hydrochloric acid (1M. 2.5 mL) and the resulting mixture was stirred at room temperature for 5h. Potassium carbonate was added, and the mixture was partitioned between methylene chloride and water. The organic extract was washed with saturated aqueous sodium chloride and dried (potassium carbonate). Removal of the solvent in vacuo and purification of the residue by flash chromatography, eluting with 5% methanol/methylene chloride, provided a solid (0.36 g, 85%): m.p. 58- 59°C.
Analysis Calc. for C17H25NO5 I/IO H2O: C 62.79, H 7.81, N 4.31; found: C 62.63, H 7.81, N 4.71. Example 18 f2S -N-r2-f3-Cvclopentvloxv-4-methoxvphenvnethvll-2.3-dihvdroxvpiDpanamide and Isohutvl N-r2-f3-cvclopentvloxv-4-methoxvphenvnethvl1carbamate
18a. (4S)-2.2-Pimet yl-l .3-djoχρlane-4-eartx?xylig acid To a solution of methyl (4S)-
2,2-d-methyl-l,3-dioxolane-4-carboxylate (0.55 g, 3.43 mmol) in methanol (15 mL) under an argon atmosphere was added lithium hydroxide monohydrate (0.15 g, 3.64 mmol). After stirring at room temperature for 2.5h, the reaction mixture was concentrated under reduced pressure. The residue was acidified with 10% HC1 and extracted with methylene chloride. The organic extract was washed with water and dried (magnesium sulfate). The solvent was removed in vacuo to provide a colorless oil, which was used without further purification.
18b. f2SVN-r2-f3-(_ clopentvloxv-4-methoxvphenvl')ethvl1-2.3-dihvdroxvpropanamide and Isobutvl N-r2-f3-cvclopentvloxv-4-methoxvρhenvnethvllcarbamate To a solution of (4S)-2,2-dimethyl-l,3-dioxolane-4-carboxylic acid (0.46 g, 3.19 mmol) in 1,2- dimethoxyethane (10 mL) under an argon atmosphere was added N-methylmorpholine (0.41 mL, 3.67 mmol) and isobutyl chloroformate (0.48 mL, 3.67 mmol). The resulting mixture was stirred at room temperature for lh, at which time was added a solution of 2- (3-cyclopentyloxy-4-methoxyphenyl)ethylamine (0.75 g, 3.19 mmol) in 1,2- dimethoxyethane (5 mL). After stirring for 6h at room temperature, the mixture was concentrated under reduced pressure. The residue was dissolved in methylene chloride and washed successively with 10% HQ, aqueous sodium bicarbonate and water and dried (potassium carbonate). The solvent was removed in vacuo and the residue was purified by flash chromatography, eluting with 3% methanol/methylene chloride to provide (2S)- N-[2-(3-cyclopentyloxy-4-methoxyphenyl)ethyl]-2,3-dihydroxypropanamide: m.p. 57- 58.5°C. Analysis Calc. for C17H25NO5: C 63.14, H 7.79, N 4.33; found: C 62.72, H 7.60, N 4.28.
Also isolated was isobutyl N-[2-(3-cyclopentyloxy-4-methoxyphenyl)ethyl]carbamate as a white solid: m.p. 54-55°C. Analysis Calc. for C19H29NO4: C 68.03, H 8.71, N 4.18; found: C 67.95, H 8.70, N 4.15. Example 19 Formulations for pharmaceutical use incorporating compounds of the present invention can be prepared in various forms and with numerous excipients. Examples of such formulations are given below.
Inhalant formulation
A compound of formula I, (1 μg to 100 mg) is aerosolized from a metered dose inhaler to deliver the desired amount of drug per use.
Figure imgf000027_0001
Procedure for Tablets:
Step 1 Blend ingredients No. 1, No.2, No. 3 and No. 4 in a suitable mixer/blender.
Step 2 Add sufficient water portion- wise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its conversion to wet granules.
Step 3 The wet mass is converted to granules by passing it through an oscillating granulator using a No. 8 mesh (2.38 mm) screen.
Step 4 The wet granules are then dried in an oven at 140°F (60°C) until dry. Step 5 The dry granules are lubricated with ingredient No. 5.
Step 6 The lubricated granules are compressed on a suitable tablet press.
Parenteral Formulation A pharmaceutical composition for parenteral administration is prepared by dissolving an appropriate amount f a compound of formula I in polyethylene glycol with heating. This solution is then diluted with water for injections Ph Eur. (to 100 ml). The solution is then sterilized by filtration through a 0.22 micron membrane filter and sealed in sterile containers.

Claims

What is claimed is:
1. A compound of formula I
Figure imgf000028_0001
or a salt thereof, where Q is a radical of formula A, B, C or D
Figure imgf000028_0002
(A), (B), (C) or (D)
Rl is lower alkyl substituted by 1 or more halogens, aryl, halo substituted aryl, aryloxyCi-3 alkyl, halo substituted aryloxyCi-3 alkyl, indanyl, indenyl, C7-11 polycycloalkyl, tetrahydrofuryl, furyl, tetrahydropyranyl, pyranyl, tetrahydrothienyl, thienyl, tetrahydrothiopyranyl, thiopyranyl, -CR4R5-C3-6 cycloalkyl, C3-6 cycloalkyl, or a C4-6 cycloalkenyl containing one or two unsaturated bonds, wherein the cycloalkyl and heterocyclyl moieties unsubstituted or substituted by 1 to 3 methyl groups or one ethyl group;
R2 is -CH3 or -CH2CH3 unsubstituted or substituted by 1 or more halogens; R3 is lower alkyl unsubstituted or substituted by one or more halogens,
-CR4R5OR4, -CR4R5NR4R9, -CR4(OR4)CR4R5OR4, 2,2-d_methyl-l,3-dioxolan-4-yl, -NR9C(O)NR4R9, -NR4R9, -S(CR4R5)nCH3 where n is 0-5, or -P(O)(ORi2)2; R4 and R5 are independently hydrogen, methyl or ethyl; R5 is hydrogen, halogen, -C1-4 alkyl, halo-substituted C1-4 alkyl, -CH2NHC(O)C(O)NH2, -CH=CR4R5, cyclopropyl unsubstituted or substituted by R4, -CN, -OR4, -CH2OR4, -NR4R5, -CH2NR4R5, -C(O)R4, -C(O)OR4, -C(O)NR R5, or -C-≡CR4; provided that when R6 is OH, then R7 is hydrogen or -CH3 unsubstituted or substituted by 1 to 3 fluoro groups;
R7 is hydrogen, F, -CN, or -CH3 unsubstituted or substituted by 1 to 3 fluoro groups, or R6 and R7 together can form a keto (=O) moiety;
R8 is H, F, CN, Ci-2 alkyl optionally substituted by 1 or more fluoro groups, C(O)NR4R5, or C(O)OR4; R9 is H, -ORi , unsubstituted or substituted -(CH2)π_Ar where m is 0-2, or unsubstituted or substituted Ci-6 alkyl, wherein optional substituents comprise from one to three groups independently selected from the group consisting of -CH3 or -CH2CH3 unsubstituted or substituted by 1 or more halogens, -NO2, -Si(R4)3, -NRIQRH, - C(O)R4, -C(O)OR4, -OR4, -CN, -C(O)NRιoRl 1, -OC(O)NRioRl 1, -OC(O)Rl2, -NRlθC(O)NRiθRn, -NRioC(O)Rn, -NRioC(O)ORl2, -NRioC(O)Rl3, -C(NRio)NRlθRll, -C(NCN)NRιoRπ, -C(NCN)SR9, -NRioC(NCN)SR9 , -NRioC(NCN)NRioRl 1, -NRioS(O)2Rl2, -S(O)m'Ri2 where m' is 0-2, -NRioC(O)C(O)NRioRll, -NRioC(O)C(O)Rlθ, thiazolyl imidazolyl, oxazolyl, pyrazolyl, triazolyl, and tetrazolyl; RlO is -ORll or -Rπ;
Rl is hydrogen, or -C1.4 alkyl unsubstituted or substituted by one to three fluoro groups; or when Rio and Rl 1 are comprise part of the group -NRioRl 1 they may together with the nitrogen form a 5 to 7 membered ring which may contain at least one additional heteroatom which is O, N, or S;
Rl2 is -Cι_4 alkyl unsubstituted or substituted by one to three fluoro groups; Rl3 is oxazolidinyl, oxazolyl, thiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl, oxadiazolyl, or thiadiazolyl, wherein each of these heterocyclic rings is connected through a carbon atom and each may be unsubstituted or substituted by one or two Cι_2 alkyl groups; Rl4 is OH or ORi2;
Rl5 is unsubstituted or substituted -(CH2)mAr where m is 0-2, or unsubstituted or substituted Ci-6 alkyl, wherein optional substituents comprise from one to three groups independently selected from the group consisting of -CH3 or -CH2CH3 unsubstituted or substituted by 1 or more halogens, -NO2, -Si(R4)3, -NRIQRH, -C(O)R4, -C(O)OR4, -OR4, -CN, -C(O)NRιoRll, -OC(O)NRioRll, -OC(O)Ri2, -NRιoC(O)NRιoRl 1, -NRιoC(O)Rι 1, -NRιoC(O)ORi2, -NRlθC(O)Rl3, -C(NRiθ)NRιoRll, -C(NCN)NRioRll, -C(NCN)SR9, -NRioC(NCN)SR9 , -NRιoC(NCN)NRioRll, -NRιoS(O)2Rl2, -S(O)m'Ri2 where m' is 0-2, -NRioC(O)C(O)NRlθRl 1, -NRlθC(O)C(O)RlO, thiazolyl, imidazolyl, oxazolyl, pyrazolyl, triazolyl, and tetrazolyl;
Ar is 2-, 3- or 4-pyridyl, pyrimidyl, pyridazyl, 2-imidazolyl, morpholino, or phenyl; Xl is YR2, halogen, nitro, -NR4R5, or formyl amine; X2 is O or NR4; X3 is hydrogen or X\;
Y is O, S, SO or SO2; Z is O or NCN; provided that a) Z is NCN only when R3 is -NR4R5 or -S(CR4R5)nCH3; or b) when Xi is -NR4R5 or formyl amine, then Rl is not CH3 or C2H5 when X2 is O and X3 is H or halogen; or c) when R3 is CR4R5NR4R9, and X2 is O, and Ri is phenyl, then one of R6, R7, or R8 is other than H; or d) when Z is NCN, and Xi is YR2, and Y is O, and R2 is CH3 and R3 is NH2, and R9 is H, OH, OCH3 or CH3, and R8 is H, and R6 and R7 are both hydrogen, or are hydrogen and methyl, hydrogen and CF3 or hydrogen and ethyl, and X2 is O, then Rl is not CF3, CF2H, or CF2CF2H; or e) when Z is NCN, and X is YR2, and Y is O, and R2 is CH3 and R3 is NH2, and R9 is H, OH, OCH3 or CH3, and R8 is H, and R6 and R7 are both hydrogen, or are hydrogen and methyl, hydrogen and CF3 or hydrogen and ethyl, and X2 is NR4 and R4 is CH3, then Ri is not CH3; or f) when Q is A, and X2 is O, Ri is aryl or halo-substituted aryl, Rg is halo or OR4, R7 is H, R8 is CH3 or CH2F and R9 is H or C1.3a.kyl, then R 5 is not lower alkyl, mono or dichlorosubstituted lower alkyl, or unsubstituted or subsitituted phenyl; or g) when Q is B, and X2 is O, Ri is aryl or halo-substituted aryl, R7 is H, K is CH3 or CH2F, R9 is H or C1.3a.kyl, then Rg is other than halo or OR4.
2. A process for making a compound of formula I according to claim 1 which process comprises one or more of the following steps: a) forming a salt; b) treating an amine with a lower alkyl acylating agent to form the corresponding amide; c) treating an amine with biuret to form the corresponding imidodicarbamide; d) hydrolyzing the product of an amine treated with trimethylsilyl isocyanate to form the corresponding urea; e) treating an amine with cyanodithioiminiocarbonate to form the corresponding N2-cyano-S-methyl-N^ -isothiouriedo; f) treating an N2-cyano-S-methyl-N^- isothiouriedo with an amine to form the corresponding N'-cyanocarboximidamide; g) treating a amine with a mixture comprising (4S)-2,2-dimethyl-l,3- dioxolane-4-carboxylic acid and isobutyl chloroformate in the presence of an organic base to form the corresponding 2,3-dihydroxypropanamide and the corresponding carbamate; h) treating an amine with 4(R)-2,2-dimethyl- 1 ,3-dioxaolane-4-carboxylic acid to form the corresponding 2,2-dimethyl- 1 ,3-dioxolane-4-carboxamide; i) treating an amine with trimethyl phosphonoformate to form the corresponding phosphonoformamide; j) reacting an amine with dimethoxyformylphosphonyl chloride; k) treating an aminopropionitrile with acetoacetyl chloride to form the corresponding 2-acetoxyacetamide;
1) hydrolyzing a protected aminoacetamide to form the corresponding 2- aminoacetamide; or m) treating an amine with a sulfonating agent to form the corresponding sulfonamide.
3. A composition of matter comprising a compound of formula I according to claim 1 in admixture with an excipient
4. A method for treating allergic and inflammatory diseases which comprises administering to a mammal in need thereof an effective amount of a compound of
Formula I either alone or in admixture with a pharmaceutically acceptable excipient
PCT/US1994/009308 1993-08-19 1994-08-19 Phenethylamine compounds WO1995005386A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US08/596,197 US5710180A (en) 1994-08-19 1994-08-19 Phenethylamine compounds
JP7507173A JPH09502170A (en) 1993-08-19 1994-08-19 Phenethylamine compound
EP94925286A EP0714397A1 (en) 1993-08-19 1994-08-19 Phenethylamine compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10918893A 1993-08-19 1993-08-19
US08/109,188 1993-08-19

Publications (1)

Publication Number Publication Date
WO1995005386A1 true WO1995005386A1 (en) 1995-02-23

Family

ID=22326275

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/009308 WO1995005386A1 (en) 1993-08-19 1994-08-19 Phenethylamine compounds

Country Status (3)

Country Link
EP (1) EP0714397A1 (en)
JP (1) JPH09502170A (en)
WO (1) WO1995005386A1 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014432A1 (en) * 1996-10-02 1998-04-09 Janssen Pharmaceutica N.V. Pde iv inhibiting 2-cyanoiminoimidazole derivatives
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2193808A1 (en) 1999-08-21 2010-06-09 Nycomed GmbH Synergistic combination
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066658A (en) * 1988-11-10 1991-11-19 Ortho Pharmaceutical Corporation Substituted hydroxyureas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT65903A (en) * 1990-07-10 1994-07-28 Smithkline Beecham Corp Oxamides, process for preparing them and pharmaceutical compositions containing them
KR930703262A (en) * 1990-11-06 1993-11-29 스튜어트 알. 슈터 Imidazolidinone Compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066658A (en) * 1988-11-10 1991-11-19 Ortho Pharmaceutical Corporation Substituted hydroxyureas

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0714397A4 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051718A (en) * 1996-10-02 2000-04-18 Janssen Pharmaceutica, N.V. PDE IV inhibiting 2-cyanoiminoimidazole derivatives
WO1998014432A1 (en) * 1996-10-02 1998-04-09 Janssen Pharmaceutica N.V. Pde iv inhibiting 2-cyanoiminoimidazole derivatives
EP2193808A1 (en) 1999-08-21 2010-06-09 Nycomed GmbH Synergistic combination
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
US7153824B2 (en) 2003-04-01 2006-12-26 Applied Research Systems Ars Holding N.V. Inhibitors of phosphodiesterases in infertility
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3718557A2 (en) 2013-02-25 2020-10-07 Bausch Health Ireland Limited Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
EP3492106A1 (en) 2013-08-09 2019-06-05 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP3884935A1 (en) 2013-08-09 2021-09-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Also Published As

Publication number Publication date
JPH09502170A (en) 1997-03-04
EP0714397A4 (en) 1996-06-26
EP0714397A1 (en) 1996-06-05

Similar Documents

Publication Publication Date Title
US5393788A (en) Phenylalkyl oxamides
US5602173A (en) Compounds useful for treating allergic and inflammatory diseases
WO1995005386A1 (en) Phenethylamine compounds
US5602157A (en) Compounds useful for treating allergic and inflammatory diseases
JP3251587B2 (en) Compounds useful for treating inflammatory diseases and inhibiting tumor necrosis factor production
US6300372B1 (en) 3-Cyano-3-(3,4-disubstituted) phenylcyclohexyl-1-carboxylates
WO1993015045A1 (en) N-(3-phenylpropyl)oxamic acid, oxamate, and oxamide derivatives
WO1993015044A1 (en) N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as tnf and pde iv inhibitors
EP0749417A1 (en) Cyano compounds and preparations thereof
WO1995009836A1 (en) Cyanocyclohexane compounds, compositions, and uses thereof
US5780667A (en) Compounds, compositions and treatment of allergies and inflammation therewith
JPH09503505A (en) Compounds, compositions and treatment of allergies and inflammation
US5710180A (en) Phenethylamine compounds
US5723681A (en) 3,3-(disubstituted)cyclohexan-1-01 dimers and related compounds
WO1995009837A1 (en) Cyano compounds
US5990119A (en) 1,4,4-(trisubstituted)cyclohexane monomers and related compounds
US5795918A (en) 1,3,3-(Trisubstituted)cyclohex-1-ene dimers and related compounds
US5777176A (en) 4,4-(disubstituted)cyclohexan-1-ol dimers and related compounds
US5777160A (en) 1, 4, 4-(trisubstituted) cyclohex-1-ene dimers and related compounds
US5900417A (en) 1,3,3-(Trisubstituted)cyclohexanemonomers and related compounds
EP0794774A1 (en) 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
WO1996020159A1 (en) 3,3-(disubstituted)cyclohexan-1-ylidine acetate monomers and related compounds
EP0799181A1 (en) 3,3-(disubstituted)cyclohexan-1-carboxylate dimers and related compounds
TW200534846A (en) Compounds useful for the treatment of diseases
WO1999052847A1 (en) Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 08596197

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1994925286

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994925286

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994925286

Country of ref document: EP